Self-administered multiplex universal radiation indicator

A self-sustained POC device integrates sample preparation and analysis to detect leukocyte proteins and transcripts, addressing the limitations of existing POC assays by enabling rapid, accurate radiation exposure assessment without external power, suitable for mass-casualty scenarios.

WO2026236658A1PCT designated stage Publication Date: 2026-11-12THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA +4
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027358
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current point-of-care (POC) radiation dosimetry assays are cumbersome, requiring trained personnel and specialized equipment, making them unsuitable for rapid triage in mass-casualty scenarios, and existing lateral flow immunoassays (LFIs) do not integrate sample preparation and analysis for intracellular biomarkers like RNA and proteins.

Method used

A self-sustained, unpowered POC device integrating sample preparation and analysis, using a vertical flow immunoassay (VFI) to detect leukocyte proteins and transcripts from whole blood, enabling end-to-end processing and detection without external power.

Benefits of technology

The device allows rapid distinction between radiation-exposed and non-exposed individuals by measuring intracellular biomarkers, providing accurate results within 30 minutes using a simple, cost-effective, and user-friendly system suitable for untrained personnel.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026027358_12112026_PF_FP_ABST
    Figure US2026027358_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Provided herein are devices and related methods for detecting a marker from a sample. The devices do not require any electrical power, are robust and reliable, such that detection may occur on-site without any need for laboratory-trained individuals or technical personnel. The marker may be a biomarker from a whole blood sample. The biomarker may be a marker indicative of radiation exposure. The devices incorporate a vertical flow assay module with a sample preparation module that can be reliably used in the field, including for self-use.
Need to check novelty before this filing date? Find Prior Art

Description

Atty Ref. 341049: 61-24 WOSELF-ADMINISTERED MULTIPLEX UNIVERSAL RADIATION INDICATORCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of priority to U.S. Provisional Patent Application Numbers 63 / 803,217 and 63 / 803,160, each filed May 9, 2025, each of which are incorporated by reference herein.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

[0002] This invention was made with government support under Grant No. AI148307 awarded by the National Institutes of Health. The government has certain rights in the invention.BACKGROUND

[0003] In a nuclear or radiological mass-casualty incident, distinguishing between exposed vs. non-exposed individuals is a first screening step to efficiently organize medical countermeasure response and improve the outcome of the population. Thus, the first triage may include testing tens or hundreds of thousands of individuals in a timely matter.Therefore, there is a need in the art for point-of-care (POC) radiation dosimetry assays that are simple enough to be used by untrained personnel, directly in the field or at home, to achieve a rapid dispatch, data collection, analysis, and interpretation. Provided herein are devices and methods for SELF -ADMINISTERED MULTIPLEX UNIVERSAL RADIATION AND ANALYSIS INDICATOR (SAMURAI). More broadly, provided herein are methods and devices for the detection of one or more markers in a sample.

[0004] Distinctive transcript and protein expression patterns from leukocytes present in whole blood (WB) can be correlated with different radiation doses. For example, distinctive transcript and protein expression patterns from leukocytes in WB as biomarkers for radiation doses are advantageous for use in rapid biodosimetry tests because, they are, for example, directly accessible from biofluid, thus facilitating less invasive access to sample and their detection can be performed using fast and multiparametic assays. Currently, POC detection of distinctive transcript and protein expression patterns by integrating sample preparation which is able to, for example, process and isolate cellular components compatible with a multiplex downstream assay is still needed. Provided herein are devices and methods that satisfy thisAtty Ref. 341049: 61-24 WOneed including, for example, the multiplex detection of both intracellular transcripts and proteins revealing comprehensive biological information to distinguish between exposed and unexposed populations following an ionizing radiation event.

[0005] In a nuclear or radiological incident, first responders must quickly and accurately measure radiation exposure among civilians, as medical countermeasures are radiation dosedependent and time-sensitive. Cytogenic methods are considered the gold standard for determining absorbed radiation dose after such an event. However, those cell-culture based assays are time-consuming and require specialized equipment and trained personnel, making them unsuitable for a rapid and high-throughput POC triage after a mass-casualty scenario. In addition, in the context of a radiological or nuclear incident, infrastructures will likely be compromised, and only minimal resources available, thus requiring the ability to perform the first phases of triage and medical management in a resource limited environment.

[0006] To provide a faster and simpler alternative to such tests, omics-based studies have identified multiple biomarkers for biodosimetry or radiation injury, accessible after a minimally invasive sample collection from diverse biofluids and easily quantifiable through fast analysis. Among these biomarkers, genes and proteins from leukocytes have shown potential for the reconstruction of the physical absorbed radiation dose or the prediction of clinical outcomes of the exposure. In addition, RNA and protein biomarkers can provide complimentary information. For example, RNA markers inform on early pathway alterations after radiation injury that can predict damage and implicate downstream targets for mitigation.

[0007] With their simplicity and low-cost, POC devices, for example, lateral flow immunoassays (LFIs), are well suited for use in resource limited settings. Currently, LFIs are widely available to detect proteins such as the human chorionic gonadotropin for pregnancy tests of the thyroid stimulating hormone for thyroid disorders, and gene transcripts such as RNA from HIV, SARS-CoV-2 or HCV. However, all of those POC tests focus on the detection of biomarkers circulating in biofluids such as urine, saliva, or whole blood.Consequently, those traditional LFIs do not require sample preparation because the target is immediately available in the biofluid. For RNA-based assays the workflow also requires several additional steps such as RNA extraction and purification, retro-transcription, amplification of the target RNA, and it monitoring, via, for example, optical or electrical means. Therefore, for the above-mentioned RNA-based tests, none have been fully integratedAtty Ref. 341049: 61-24 WOinto a POC system, because one or more of the aforementioned steps must be completed off-chip. For example; clinical staff is needed for sample collection, the sample preparation requires intervention of laboratory standard practices and supplies, the reverse transcription and amplification steps have to be performed on bench, or some steps still require the intervention of trained personnel or the use of large power-supplied automated laboratory equipment.

[0008] Radiation biodosimetry genes and proteins have been identified as intracellular, found in, for example, leukocytes or specific leukocyte subsets (T cells, B cells, etc.), thus requiring an additional step for the isolation of the protein and / or transcripts prior to detection using a POC assay. As a result, to provide a rapid protein- and gene-based assay for radiobiological triage, there is a need for a complete handheld POC system integrating both sample preparation, sample processing, and analysis for the detection and quantification of radiation biomarkers.SUMMARY

[0009] Provided herein are devices and methods that address the above problems by providing a self-sustained, unpowered, POC device able to measure a marker in a sample. For a radiation-specific application, the POC device measures one or more leukocyte protein and transcripts levels to distinguish between exposed and non-exposed individuals following an ionizing radiation event. The devices and methods provided herein are particularly useful in that they are able to completely end-to-end run in a sample-to-answer configuration. By integrating the sample preparation (including from a self-collected sample by an individual) components with endpoint measurement components, such as by vertical flow immunoassay (VFI), an all-in-one integrated device is provided that efficiently and reliably processes the sample and provides an end-point detection status of a marker that may be in the sample.

[0010] Provided are various devices for detecting a marker from a fluid sample, including point-of-care (POC) devices. For example, the device may comprise: a sample container comprising: a passage configured to receive the biofluid sample into a sample chamber; a sample container material positioned on a bottom surface of the sample container to fluidically seal the sample container; a sample container piercing insert opposably positioned to the sample container material to form a sample container volume between the sample container piercing insert and the sample container material; a top vessel configured toAtty Ref. 341049: 61-24 WOoperably connect to the sample container, wherein the top vessel comprises: a primary buffer solution chamber; a waste chamber; one or more lateral buffer solution chambers; a bottom film that fluidically seals the primary buffer solution chamber and the lateral buffer solution chambers from the sample container, wherein the top vessel is configured for positioning relative to the sample container so that the sample container piercing insert controllably pierces the bottom material for biofluid communication between the top vessel and the sample container; a membrane housing configured to operably connect to the sample container, wherein the sample container is positioned between the top vessel and the membrane housing, the membrane housing containing: a membrane housing piercing insert configured to controllably pierce the sample container material; a membrane pad positioned beneath the piercing insert; a bottom cap connected to a bottom surface of the membrane housing and configured to support the membrane pad; wherein: optionally the sample container material and / or bottom material comprises a controllably pierceable film, sponge or a foam-like material; optionally the piercing insert is a piercing disk insert inserted in a cylindrically-shaped container or vessel.

[0011] The waste chamber and the buffer solution chamber may be positioned in the top vessel such that the waste chamber and the buffer solution are vertically aligned with at least one pierce tip configured to pierce the bottom film to fluidically access the buffer solution chamber at a first pierce location and to fluidically access the waste chamber at a second pierce location.

[0012] The sample chamber may be removably connected to the membrane housing to provide a membrane housing removed configuration, wherein in the membrane housing removed configuration the membrane housing is configured to optically receive a magnifying cap to optically image the membrane pad to detect the presence or absence of one or more biomarkers.

[0013] The membrane housing preferably contains a vertical flow immunoassay (VFI).

[0014] The passage is sized to receive a whole blood collection device that dispenses the biofluid that is a whole blood sample into the sample chamber.

[0015] The sample chamber is configured to receive a whole blood sample volume between 1 pL and 10 mL, including by corresponding sizing the volume of the sample chamber.Atty Ref. 341049: 61-24 WO

[0016] The sample chamber may further comprise a capture agent immobilized on a wall that forms the sample container. The capture agent may be selected from the group consisting of DNA probes, RNA probes, an antibody, a polypeptide, and any combination thereof. The capture agent may be an antibody selected from the group consisting of: S9.6 antibody, anti-CD3, anti-CD19, and anti-CD45.

[0017] The sample container may be formed of a material comprising polycarbonate, polypropylene, styrene, or any combination of these.

[0018] Also provided herein are methods of using any of the POC devices described herein to detect presence (or confirm absence) of a marker in a fluid, including for example, a nucleic acid (NA).

[0019] For example, provided is a method of detecting a presence or an absence of a biomarker in a whole blood sample by providing any of the devices disclosed herein. The steps may comprise: loading a primary buffer solution comprising a red blood cell lysis buffer solution into the primary buffer solution chamber; loading a lateral buffer solution comprising a leukocyte cell lysis buffer solution into at least one lateral buffer solution chamber; loading the whole blood sample through the passage into the sample chamber; piercing the top vessel bottom film to fluidically introduce the primary buffer solution to the whole blood sample; performing a first incubation step to process red blood cells and to immobilize leukocytes on a wall of the sample chamber; inverting the device; fluidically introducing any excess primary buffer solution to the waste chamber; sealing the waste chamber and piercing the one or more lateral buffer chambers to release the lateral buffer solution into the sample chamber; inverting the device a second time; performing a second incubation step to process the immobilized leukocytes; piercing the sample container film thereby fluidically introducing the leukocyte lysis buffer to the membrane pad; removing the sample chamber from the membrane housing; and optically imaging the membrane pad for the presence of the biomarker, thereby detecting the presence or absence of the biomarker.

[0020] The biomarker may be selected so as to indicate an exposure to radiation.

[0021] The step of piercing the top vessel bottom film to fluidically introduce the primary buffer solution to the biofluid may comprise applying a physical force to the top vessel in: a downward direction; and / or a rotational direction relative to the sample chamber.Atty Ref. 341049: 61-24 WO

[0022] The step of fluidically introducing any excess buffer solution to the waste chamber may comprise piercing the film at a waste chamber location by further continuing to rotate the top vessel relative to the sample container.

[0023] The step of sealing the waste chamber and piercing the lateral buffer chambers to release the later buffer solution may comprise applying a second physical force to the top vessel in: a downward direction for a second time; and / or a continuing rotational direction relative to the sample chamber.

[0024] The method may further comprise the step of heating the device during a third incubation step.

[0025] The first incubation step may be for a first incubation time period selected from the range of 10 s to 10 min and the second incubation step may be for a second incubation time period selected from the range of 10 s to 15 min.

[0026] The leukocyte cell lysis buffer solution may further comprise a DNA probe solution and / or an RNA probe solution, in addition to solution components that lyse the leukocyte or white blood cell.

[0027] The method may be used as a biodosimetry assay.

[0028] The method may be for detection of a plurality of biomarkers, including a plurality of intracellular biomarkers, wherein the biomarker(s) are selected from the group consisting of: proteins, DNA sequence, RNA sequence, radiation responsive genes, and any combination thereof.

[0029] The biomarker may comprise an intracellular protein selected from the group consisting of: ACTN1, DDB2, FDXR, phosphor-p53, TSPYL2, and any combination of thereof.

[0030] The biomarker may be a radiation responsive gene that is an up-regulated gene or a downregulated gene, including the radiation responsive gene selected from the group consisting of CDKN1A, DDB2, TYMS, CD79B, MYC, EOMS, and any combination thereof.Atty Ref. 341049: 61-24 WO

[0031] The method may have a radiation detective sensitivity selected from a range of 0.1 Gy to 3 Gy, including 2 Gy. This is achieved by selecting relevant genes and providing corresponding VFI tailored to the desired sensitivity.

[0032] The method may further comprise the step of collecting the whole blood sample from an individual, including from within 72 hours of a putative radiation exposure event, such as collecting by a finger-stick. In this manner, the collection may be by self-collection by the user of the device.

[0033] The membrane pad layer may correspond to a VFI.

[0034] Without wishing to be bound by any particular theory, there may be discussion herein of beliefs or understandings of underlying principles relating to the devices and methods disclosed herein. It is recognized that regardless of the ultimate correctness of any mechanistic explanation or hypothesis, an embodiment of the invention can nonetheless be operative and useful.DESCRIPTION OF DRAWINGS

[0035] FIG. 1 is a photograph of an exemplary point-of-care (POC) biodosimetry device (SAMURAI kit - top panel) and assembled in hand (bottom panel).

[0036] FIG. 2 is a schematic of an exemplary usage and overall workflow of a POC device (e.g., SAMURAI kit) for assessing a population potentially exposed to a biologically-relevant event such as an unknown radiation dosage. As illustrated, the kit is assembled and can input a whole blood sample from a finger-prick to assist in classifying a whole population as an exposed sub-population or a non-exposed sub-population, for appropriate subsequent tailored handling and treatment.

[0037] FIG. 3A-3B provides ROC Curves for prediction of x-ray exposure based on Percent Positive values of BAX (FIG. 3A) and p53 (FIG. 3B) in unexposed (0 Gy) and exposed (1-5 Gy) human blood leukocytes, days 1-3 combined after irradiation. Boruta algorithm

[0017] was used to select the most important predictors to classify samples as irradiated. Time since irradiation (1-3 days) did not pass the Boruta testing, suggesting that the data from different days could be combined in the context of this classification. TheAtty Ref. 341049: 61-24 WOretained predictors (Percent Positive in lymphocytes and in CD3+ T-cells) were implemented for sample classification using the stacking machine learning approach.

[0038] FIG. 4 are ROC curves for prediction of x-ray exposure based on MFI values of top performing biomarkers in unexposed (0 Gy) and exposed (2 Gy) in human leukocytes on days 2 and 7 post x-irradiation.

[0039] FIG. 5 is a dose-response and ROC Curves for prediction of x-ray exposure based on MFI values of top performing biomarkers (DDB2 and FDXR) in unexposed (0 Gy) and exposed (1-4 Gy) C57BL / 6 mouse leukocytes, on days 1 and 7 post x-irradiation

[0040] FIG. 6A-6C is a DDB2:CD79B ratio as a function of dose or time after exposure (FIG. 6D). control samples are represented by blue dots, irradiated by red. Classification of samples as exposed or not yielded an AUROC of 1, with the exception of the human TBI (FIG. 6E) and NHP TBI at 60 days after exposure (FIG. 6F).

[0041] FIG. 7 illustrates detection of radiation induced DDB2 and BAX expression using conventional ELISA methods.

[0042] FIG. 8 : Dose-response curves of DDB2 and P-tubulin proteins using different antibody pairs.

[0043] FIG. 9 : Schematic of a nucleic acid assay using DNA probe.

[0044] FIG. 10A: Principle of a multiplex sandwich immunoassay performed in the VFI FIG. 10B: Actual membrane with positive signal after a VFI run

[0045] FIG. 11 A: Exploded view of an instant device (OMTEST kit). FIG. 11B Pictures focusing on 3 main components: (1) housing membrane containing the pad holder and closed with the magnifier cap, (2) assay buffer pad capsule and (3) washing buffer pad capsule.

[0046] FIG. 12: Schematic overview of a complete 20 min- OMTEST assay operation performed from a blood fingerstick during the Inspiration4 mission.

[0047] FIG. 13A: Smartphone-compatible system for picture acquisition oof the VFI membrane. FIG. 13B VeriFASTTM App developed to analyze colorimetric signal on VFI membraneAtty Ref. 341049: 61-24 WO

[0048] FIG. 14: A Sample Preparation Module (SPM) and its sequential workflow to collect whole blood, lyse red blood cells, bind and lyse leukocytes, anneal DNA probes with heating step and transfer sample to membrane housing.

[0049] FIG. 15 illustrates multiplex VFI membranes and attendant characterization thereof. Panel A (top of figure): Multiplex VFI membranes run with the amplicons together (Multiplex), with each amplicon individually or without the template (Negative). Graph (top right of figure) represents quantification of signal intensity from images. ND = not detected (n = 3). Panel B: Dose response of the three amplicons in the nucleic acid VFI. Panel C: Intra- and inter-assay coefficient of variation (CV). Panel D: Receiver operating characteristic (ROC) curve analysis of nucleic acid VFI to discriminate non-exposed controls (NI) from exposed samples (IR). Panel E: VFI membranes of non- irradiated (0 Gy) and 1 and 2Gy-irradiated samples. Panel F: Dose response of CDKN1A + DDB2 measured with the VFI (left) or by qPCR (right).

[0050] FIG. 16: Images of analyte arrays demonstrating the multiplex detection of SARS-CoV2 gene and antibodies onto the same membrane using spiked artificial saliva samples.

[0051] FIG. 17: POC device workflow summary broken into panel steps 1-14.

[0052] FIG. 18: View of a POC device (SAMURAI) with the sample preparation module (SPM) and Vertical Flow Immunoassay (VFI) module.

[0053] FIG. 19: Dose-response curves of P2m and DDB2 proteins obtained on VFI membranes (top panels a). Representative pictures of VFI membranes run in multiplex with different concentrations of P2m and DDB2 proteins (bottom panels b).

[0054] FIG. 20: Multiplex VFI membrane for the detection of CDKN1 A, DDB2 and MRPS5 transcripts amplified by isothermal method as well as P2m and DDB2 proteins.

[0055] FIG. 21A Hemoglobin release measured in supernatant of WB incubated with PBS (negative control), ACK, EL and water (H2O) buffers for 10 s and 10 min. FIG. 21B MTT assay performed on cell pellet resuspended and obtained after WB incubation in ACK, EL (10 min) and water (10 s and 10 min) and incubated on anti-CD45-coated plate.

[0056] FIG. 22: a) Og-VFI membranes and quantification of their signal spots after incubation with no samples (0), IgM only, CRP only or in multiplex (IgM + CRP). b) CRPAtty Ref. 341049: 61-24 WOand IgM dose-response curves. Dotted line represents LOD c) Intra- and inter-assay CV across CRP and IgM assays, d) Representative picture of a Og-VFI membrane showing heterogeneity in signal distribution, e) Quantification of intensity distribution across 3 Og-VFI membranes replicates.

[0057] FIG. 23A-23F illustrates various process steps for an exemplified POC device.

[0058] FIG. 24 is an illustration of a POC device having different introduced solutions, including a sample material (whole blood), RBC lysis buffer and cell lysis buffer.

[0059] FIG. 25 is an illustration of a POC device including a capture agent that is an antibody on a surface of the sample chamber for binding a WBC.

[0060] FIG. 26 illustrates intended usage and overall workflow of the POC device that is a SPEED-AHEAD kit.DETAILED DESCRIPTION

[0061] The devices and methods provided herein are useful in a wide range of applications. One preferred use is for the point-of-care (POC) detection of radiation exposure among civilians in a nuclear or radiological incident.

[0062] Of particular relevance, the devices, kits and methods provided herein are tailored to biodosimetry applications, with specific optimized panels of proteins and NA signatures in the biodosimetry panels, tailored to whole blood samples and intracellular biomarkers.

[0063] The devices are configured to ensure that fluid is appropriately collected, processed and detected. Accordingly, there is controlled and directed fluid flow between the various components when desired by the user. The devices are versatile in that the components are functionally integrated and provide continuous processing of the sample, ranging from sample preparation to detection. The final detection can be by delivery of fluid to a sensor that is provided in the form of a membrane that analyzes / interrogates the sample to thereby characterize the sample. This membrane can be a VFI membrane having an array of capture agents (also referred herein as probes) to capture a marker, such as to provide characterization of a presence or absence of a specific protein or nucleic acid, thereby detecting a marker in the sample. The “sensor membrane” can be static or can be reversibly activated via chemistry, such as by adding a detachment reagent (e.g. enzyme) to expose theAtty Ref. 341049: 61-24 WOprobes to a next cycle of detection allowing a more continuous analysis. On the membrane or the device container, some sensors can be added for physical measurements such as pH, temperature and / or electrical signals (e.g. TEER).

[0064] Example 1: Self- Administered Multiplex Universal Rapid Indicator (SAMURAI) kit.

[0065] Provided in this example is a powerless (no battery power) point- of-care biomarkers diagnostic platform (Self- Administrated Multiplex Universal RApid Indicator (SAMURAI kit)), including for the detection and quantification of intracellular leukocyte biomarker proteins and transcripts (e.g., relevant for ionizing radiation exposure determination) using a Vertical Flow Immunoassay (VFI) (FIG. 1). The platform integrates all components required to span a process from sample collection and preparation, bioassay, detection, automated data analysis and reporting, offering to the user a versatile tool to quickly and reliably distinguish unexposed vs exposed individuals in under 30 minutes during triage after a radiological or nuclear mass casualty scenario. The flexibility of the platform in measuring protein and transcripts simultaneously can enhance performance, and make it readily compatible for detection of other threats, or monitoring clinical biomarkers for disease management. This provides a broad appeal for various commercially-relevant applications.

[0066] Relevant activities include SAMURAI integrated device design and rapid prototyping by 3D printing and soft injection molding; fluidic and biological testing of the SPM module, verification of commercial lancet and collection device for input into the SPM, development and characterization of the SPM heating system; VFI module optimization for the SAMURAI detection, membrane multiplex printing; integration of the benchtop bioassay and reagents formulation into the SAMURAI kit; clinical usability and initial performance review to assess the capacity of the SAMURAI kit to differentiate the two populations (unexposed vs. exposed); establish specifications of the software App; evaluation of reagent stability and storage condition and preparation for mass quality manufacturing and registration documentation.

[0067] Provided are benchtop versions of the sandwich protein immunoassay and the DNA:RNA hybrid transcript assay for incorporation into an integrated SAMURAI kit. Dose response and the limits of detection of these bioassays are provided for ex vivo irradiated human and NHP samples. Transitioning these benchtop assays to a porcine model facilitatesAtty Ref. 341049: 61-24 WOinitial in vivo testing in a large animal model, and participate as a second site in ex vivo testing of the integrated SAMURAI kit and validation studies for in vivo NHP studies.

[0068] The SAMURAI Kit is validated to inform triage by distinguishing radiation exposed from unexposed individuals after a radiological or nuclear incident. In this aspect, radiation biomarker protein and RNA bioassays are developed and integrated in the vertical flow immunoassay (VFI) of the SAMURAI kit that is a self-administered, powerless (no battery power), and cost-efficient point-of-care system based on a safe “tube and cap” user interface design that automates the entire test workflow. A sample preparation module is optimized in order to receive whole blood, lyse red blood cells, capture and lyse the leukocytes to extract proteins and RNA, and perform DNA:RNA hybridization under heating conditions controlled by a chemical exothermic self-heating pad. Then, this module is connected to the VFI capillary detection device to proceed to the assay where an interface facilitates VFI array membrane imaging by commercial smartphones, including via a software implemented process, including an App, to acquire signal spots. Then, images are transmitted to a cybersecure cloud-based server where they are analyzed and processed by a software that directly provides a screening result. This system is tested and validated using ex vivo human samples as well as ex vivo and in vivo large animal models for providing robust performance data following FDA guidelines. With this, the kit is a TRL 6 versatile tool capable of assessing an individual’s radiation level in less than 30 minutes using an integrative proteo-transcriptomic signature from a minimally invasive fingerstick blood biopsy, possibly providing better indicators of exposure, reducing false positives, and enhancing diagnostic performance, while minimizing need for on the ground professionals collecting and processing samples.

[0069] Protocol optimization for VFI application: Sandwich immunoassay development for protein detection involves identifying at least one antibody pair for each protein that provides a strong signal -to-noise ratio for accurate detection on a standard ELISA plate. The platform is, of course, compatible with commercially available antibodies and standard sample preparation procedures. Antibody pairs are identified for the detection of, for example, 3-4 proteins.

[0070] DNA probes for transcript detection: Identify at least two DNA probes able to bind each gene of interest (initially DDB2 and CD79B, followed by CDKN1 A and MYC) at two different specific sequences within each RNA molecule to provide binding sites for a captureAtty Ref. 341049: 61-24 WOprobe coated on a plastic substrate and for signal amplification using a detection antibody. Ensure specificity by performing sequence alignment in silico and sequencing of captured RNA. Performance can be validated compared with standard qRT-PCR. In this manner, provided are DNA probe sequences for the detection of, for example, at least 2 genes.

[0071] Common lysis buffer (for RNA and protein): Identify a common chemical method for cell lysis for the human and NHP models that allows high recovery yield of both protein and RNA without degradation when assayed immediately. Assess the best approach using assays identified above compared with standard sample preparation. In this manner, we establish common cell lysis protocols for integrated analysis of protein and RNA.

[0072] Optimization of the VFI module: Using successful bioassays, including as described above, we optimize the current VFI module to decrease assay time, membrane background and washing steps, while improving reproducibility. Assess different gold labeling, filters (pore sizes), membranes (material types), and test flow diffusers for optimizing fluid spatial distribution, homogeneity, and reduction in clogging issues. Optimized design of the VFI module ensures reproducible and strong colorimetric signal (at least detectable by naked eye in daylight and including with commercially available imagers and cameras, including incorporated on smart phones and the like).

[0073] Membrane printing: Develop and optimize the preparation and printing of the VFI array membrane, including the determination of the most appropriate layout, size, blocking buffer, nozzle hydrostatic pressure and antibody concentration. Printing protocol for the SAMURAI multiplex membrane including genes, proteins and controls for 100 membrane disks / batch with minimal batch-to-batch variability (<10%)

[0074] Image acquisition, analysis and software algorithm development: The apparatus allows VFI membrane pictures of appropriate quality for automated analysis, including using smartphone technology. Algorithm and software to rapidly analyze signal intensity of each spot on the VFI membrane and perform normalization operation for each protein and gene. Preferably, an accessory device compatible with iPhone 12 or higher facilitates the ability to take pictures of the VFI membrane directly from the VFI module and the software-implemented processor distinguishes signal intensity changes on a VFI membrane under ambient daylight conditions and typical moisture ranges, such as a humidity of between 20-75%.Atty Ref. 341049: 61-24 WO

[0075] Sample Preparation Module (SPM) SPM and flow colored buffer facilitates checking for any leaks and confirms appropriate and adequate circulation to the VFI module. Liquid transfer is assessed by the total volume collected by the absorbing pad in the membrane housing when connected to the VFI module. The SPM is configured to handle at least 90% sequential fluid volume transfer to the VFI module

[0076] SPM performance evaluation with biological matrix: Assess the SPM workflow process using a biological sample, such as whole blood. This includes optimization of red blood cell lysis, SPM internal coating with anti-CD3 and anti-CD19 antibodies, leukocytes capture and lysis. Workflow performance immediately assessed by measuring quantity and quality of the proteins / RNA by bioanalyzer, ELISA and PCR. The SPM, in this example application, preferably isolates non-degraded T- and B-cells for intracellular protein and gene measurements, including relevant for assessing a degree of a biologically-impactful event, such as a radiological dosage.

[0077] SPM chemical heating system: Assess different chemical heating systems for integration within the SPM to provide the required and controlled temperature for the nucleic acid assay. System performance assessed by physical (Thermal rate and stability) and biological measurements (e.g., signal amplification fold). The effect of heating step on protein integrity is evaluated with preferably no more than 5% degradation of the protein. Integrated powerless heating system to provide a constant (and controllable) temperature at a temperature that is less than or equal to 56°C for at least 10 min within the SPM chamber placed into an insulating bag.

[0078] Integrating the benchtop protein assay in the VFI module: Print capture antibodies on the VFI membrane, load detection antibodies on the conjugation pad and run (1) spiked protein both in single and multiplex and (2) whole cell lysate. Optimize the conjugation pad and VFI membrane for antibody concentrations, buffers, etc. In this manner, provided is a VFI module having a signal intensity proportional to the concentration of the protein loaded in the sample, including a signal intensity that can be optically quantified under ambient daylight conditions with an imager and processor for determining optical intensity.

[0079] Integrating the benchtop RNA assay in the VFI module: Print capture DNA probes on the VFI membrane, load gold nanoparticle-labeled S9.6 antibodies with or without detection DNA probes on the conjugation pad and run samples to determine signal intensity.Atty Ref. 341049: 61-24 WOOptimize the conjugation pad and VFI membrane for DNA probes and antibody concentrations, buffers, etc. In this manner, provided is a VFI module providing positive signal into an optical image (SNR>5) for at least one radiation responsive gene.

[0080] Combining sample preparation with the VFI module: Load whole blood within the SPM, proceed to the full workflow as established, and detect protein and / or transcript signals using the integrated VFI module. Signal intensity can be analyzed with a benchtop optical scanner and automated APP-based approach and compared. In this manner, provided is a VFI module providing positive protein and / or gene signal from whole blood using SPM processing.

[0081] Software App performance and testing to confirm appropriate read and quantification of the SAMURAI-processed membrane. Provided is a SAMURALkit-compatible App configured to read / analyze reproducibly (such as from triplicate images) processed membranes in ambient environmental conditions (daylight, 25°C, dry-to-wet).

[0082] Classification performance of the benchtop RNA and protein assays: Determination of assay dose response and limits of detection in non-human primate (NHP) blood irradiated ex vivo-. Test the detection of exposed vs. unexposed NHP blood samples using the benchtop protein and RNA assays characterizing performance by area under the ROC curve (AUROC) for sample classification. Both the lower and upper limits of detection is defined as AUROC > 0.8 and tested through at least the range of 1-8 Gy, thereby identifying the dose range for exposure detection and characterization of the performance of the individual and combined protein and RNA assays across that range.

[0083] Determination of assay dose response and limits of detection in human blood irradiated ex vivo-. Test the detection of exposed vs. unexposed human blood samples using the benchtop protein and RNA assays characterizing performance by area under the ROC curve (AUROC) for sample classification. Both the lower and upper limits of detection are defined as AUROC >0.8 and tested through at least the range of 1-8 Gy. Definition of the dose range for exposure detection and characterization of the performance of the individual and combined protein and RNA assays across that range in an ex vivo human model.

[0084] Testing and validation of the benchtop assays in a porcine model: Development of conventional RNA and protein assays for the minipig model using ex vivo irradiated blood. Test the efficacy of the protein and RNA biomarkers used for human / NHP for detectingAtty Ref. 341049: 61-24 WOradiation exposure in the pig using blood irradiated ex vivo. New probes are developed if necessary and commercial antibodies, specific for the porcine model, are purchased.Performance is assessed by AUROC for sample classification, across at least a dose range of 1-8 Gy. Detection of protein and RNA endpoints with a defined dose range for radiation exposure detection suitable for testing in a large animal model.

[0085] Testing the benchtop RNA and protein assays for the minipig model using ex vivo irradiated blood: Transition the benchtop protein and RNA assays to the minipig model using ex vivo irradiated blood. The efficacy of the assays are tested for detecting radiation exposure. Performance is assessed by AUROC for sample classification across a dose range of 1-8 Gy, and compared with the performance of the standard assays. Provided are benchtop assays with a defined dose range for radiation exposure detection suitable for testing in a large animal model.

[0086] In vivo testing of the benchtop radiation detection assays in a minipig model: Expose a cohort of 3 minipigs to radiation and obtain blood samples from the animals at 3 times before irradiation, and on days 1-7, 14, 21 and 28 following irradiations. The blood samples are immediately evaluated using the benchtop assays, and the performance of the assay are evaluated by AUROC across the first week after radiation exposure and compared with the standard assays. An initial test of the benchtop assays in vivo in a large animal model assessing the performance of radiation exposure detection across the first week after radiation exposure.

[0087] Performance characteristics of the SAMURAI kit on irradiated samples: Evaluation of the integrated SAMURAI kit using control and ex vivo irradiated human and NHP blood (=20 total; 10M / F for both). Signal intensity is calculated to assess sensitivity and specificity of the VFI platform to distinguish exposed vs. unexposed samples and compared with standard method. SAMURAI performance report to distinguish unexposed vs. exposed whole blood samples with success rate >95% in less than 30 minutes.

[0088] Stability and storage conditions: Assess the SAMURAI kit over a large timeframe simulation, in environment representing the different conditions during operational use in US (humidity, temperature, dust, etc.). Performance report of reagent stability and storage under accelerated shelf-life studies defined by DOE simulation conditions equivalent to > 1 year.Atty Ref. 341049: 61-24 WO

[0089] App validation and cloud-based data testing: Evaluate the capacity of the software App to distinguish biodosimetry status from membrane processed with the complete SAMURAI workflow and test App functionality with device using cloud-based Test Flight launch for internal testing and HIPAA data security controls. App to read and analyze SAMURAI membrane for dosimetry purpose, including an iPhone App.

[0090] Optimization for design manufacturing: Retooling for industrial manufacturing: Qualify a multi-cavity mold and validate the molding process. Quality assurance comprises microscopy inspection, mechanical, thermal and fluidic testing, as well as biocompatibility validation. Assembly processes including selection of adhesive / sealing films for reagent containers and piercing testing is assessed. Physical industrial multi-cavity steel molds for multiple parts large volume injection molding.

[0091] Reagent manufacture: Work with vendor(s) used by molecular diagnostic companies to develop protocol for regulated reagent batch manufacturing and device surface coatings. Validated protocols for reagent manufacturing and formulation packaging.

[0092] In vivo testing of SAMURAI in an NHP model: Irradiation of NHPs, sample acquisition and SAMURAI testing. Irradiate and obtain blood samples from 6 male and 6 female NHPs before and after irradiation. Part of each sample is used to test the performance of the integrated SAMURAI pre-production devices. The remainder of the samples can be shipped for validation assays. Performance assessment of SAMURAI pre-production kit on in vivo irradiated NHP samples.

[0093] Validation of in vivo irradiation detection in an NHP model: Perform conventional protein and RNA assays to compare performance with that of the SAMURAI kit. Blood samples from NHPs (=12 total; 6M / F) are collected prior to irradiation, and on days 1-7,14, 21, and 28 after irradiation and shipped. Performance of conventional assays for sample classification (exposed / non- exposed) are evaluated by AUROC (p>0.8). Performance assessment comparing conventional assay with SAMURAI kit

[0094] The SAMURAI kit is an integrated point-of-care (POC) device for field triage designed to distinguish between exposed and unexposed populations within at least the first 72h after irradiation (FIG. 2). The SAMURAI kit includes a POC sample preparation module to process whole blood from fingerstick collection and obtain a leukocyte lysate that will be transferred to a vertical flow immunoassay (VFI) module to simultaneously detect protein andAtty Ref. 341049: 61-24 WOtranscript radiation biomarkers. This workflow does not require electrical power, thus minimizing volume and cost, making the SAMURAI kit perfectly suitable for POC usage. The simplicity and convenient user interface of the SAMURAI kit allows the assay to be performed by untrained first responders or by self-testing. Membrane data can be captured and analyzed by a smartphone-based App and uploaded to a secure cloud to provide rapid and reliable results, including within 30 min from sample collection.

[0095] The SAMURAI kit is targeted for use across the population. The POC device is developed with the broadest demographics in mind as an IND (Improvised Nuclear Device) can be detonated in a large and broadly populated area. Therefore, provided is a combined protein and transcript expression assay that has been developed for widespread application profiles including sex, age, and confounding factors (such as smoking). These proteo-transcriptomic signatures have been independently validated for radiation exposure and are optimized for distinguishing non-irradiated versus irradiated individuals.

[0096] Table 1 summarizes “Indications and Usage” and Table 2 “Performance Specifications and Features”.

[0097] In the manner, as summarized in Tables 1-2, provided is a benchtop protocol fully developed and validated to discriminate between control and a 3 and / or 5 Gy dose using protein and / or transcripts. An optimized optical module for the SAMURAI kit that provide uniform signal across the membrane quantifiable through software analysis in less than 30 min. A printing protocol for the SAMURAI kit membrane that integrates both DNA probes and capture antibodies printing, as well as controls, in a new layout. A processor performing software-based instructions that can discriminate signal intensity changes on a mock SAMURAI kit membrane. Similar to the previous VFI images, we identify and adapt an image analysis algorithm for recognizing the pattern of VFI spots. Establishment of a lysis strategy able to process whole blood to provide non degraded leukocyte protein and RNA samples that can be used immediately in immunoassay. The detection of a gene signal and / or protein signal and / or combined signals using the SAMURAI kit. Data are compared between a benchtop optical scanner and the images acquired by the smartphone imager for correlating sufficient dynamic range to distinguish positive from negative test signals. Identification and selection of target protein and / or transcript biomarkers for testing in the minipig model.Atty Ref. 341049: 61-24 WO

[0098] The point-of-care SAMURAI™ diagnostic system exploits protein and gene biomarkers for rapidly and safely assessing radiation exposure by untrained individuals using a self-administrated-compatible blood sampling and processing workflow producing test results without the need of any ancillary instrumentation. The complementary domains of expertise and the network of industry and regulatory partners provide the necessary framework for producing a cost-efficient biodosimetry solution readily applicable to FDA regulatory and logistical requirements of emergency medical countermeasures. The SAMURAI kit leverages commercial and regulated device components with a well-established supply chain framework for facilitating commercialization and strategic stockpiling.

[0099] Cytogenetic methods are considered the gold standard for determining absorbed radiation dose after a radiological incident. However, those cell-culture based assays are very time-consuming, require specialized equipment and trained personnel, thus making them unsuitable for point-of-care (POC) applications and of limited throughput for large-scale screening of victims after a radiological / nuclear incident. In contrast, biodosimetry assays developed from omics- based technologies hold great potential for integration into a POC device to measure biomarkers easily accessible from biofluids using well-developed molecular assays. We identify a robust list of candidate protein and RNA biomarkers in peripheral blood cells, and we continue to validate for accurate dose reconstruction both in vivo and ex vivo up to a week after radiation exposure. We demonstrate and test protein and RNA biomarkers suitable for detection of radiation exposure and transition them towards integration into the SAMURAI device.

[0100] Protein expression for radiation biodosimetry: The FAST-DOSE (Fluorescent Automated Screening Tool for Dosimetry) bioassay system is designed to rapidly quantify the upregulation of radio-responsive intracellular proteins ACTN1, DDB2, FDXR, BAX, phospho-p53 (p53), and TSPYE2 in blood leukocytes to reconstruct absorbed dose after radiation exposure [14-16], This immunofluorescent biomarker system based on imaging flow cytometry (IFC) has made use of the human blood ex-vivo model and non-human primate (NHPs), humanized mouse (NOD-scid- gamma - Hu-NSG) and C57BL / 6 mouse models, which has allowed us to identify the top-ranking proteins across these different model and species systems. The data below summarizes individual biomarker performance using the area under the receiver operating characteristic curve (AUROC) analyses across theAtty Ref. 341049: 61-24 WOtested model systems using the same anti-human primary antibodies. This indicates good conservation of the protein response to radiation and antibody cross-reactivity across the species.

[0101] Human blood ex vivo model: We have developed a human blood cell culture model to test our 6-protein panel up to 3 days after 1-5 Gy ex vivo x-ray exposure. Measurements of cell percentages with true biomarker fluorescence intensities above background signal (“Percent Positive”) showed dose- dependent increases in lymphocytes up to 5 Gy (data not shown). To determine each biomarker’s strength in correctly classifying a sample as exposed or unexposed, we used the stacking machine learning approach

[0017] to conduct AUROC curve analysis of the top 2 performing biomarkers p53 (Panel A), and BAX (Panel B) measured in all lymphocytes and T-cells on days 1, 2 and 3 after x- ray exposure. FIG. 3A-3B shows that p53 (AUROC = 0.88) and BAX (AUROC = 0.85) are able to clearly distinguish between exposed and unexposed blood samples over the first 3 days after x-ray exposure. These data are from healthy male and female adults, aged >18.

[0102] NHP blood in vivo model: NHPs are exposed to TBI doses from 0 to 10 Gy and blood samples were collected on days 2, 4 and 8 after exposure

[0015] , To assess the diagnostic ability of the biomarkers for radiological triage

[0018] , we performed AUROC curve analysis to discriminate radiation doses below 2 Gy from doses equal to or above 2 Gy (Table 3). The results show that all 6 biomarkers individually (except for p53 at day 8), were able to discriminate these two groups with AUCs ranging from 0.741 (FDXR at day 2) to 0.996 (ACTN1 at day 2). Biomarkers DDB2, BAX, p53, and TSPYU2 performed better at the earlier time points while FDXR provided a better diagnostic power at the later time point. Overall, ACTN1 provided the best discriminating potential to identify doses < 2 Gy and > 2 Gy across all three time points.

[0103] Humanized mouse in vivo model: in our earlier work

[0015] , we measured the Mean Fluorescence Intensity (MFI) levels of ACTN1, BAX, FDXR, p53 expression in peripheral blood lymphocytes in vivo from Hu-NSG mice exposed up to 3 Gy x rays. We showed that ACTN1 at day 1, p53 + BAX at day 2 and p53 at day 3 reconstructed dose with an accuracy of ± 0.04-0.61 Gy. We similarly evaluate the performance of top biomarker candidates. For example, FIG. 4 shows that increases in MFI values of ACTN1 and p53 on day 2 are able to classify the samples from exposed (2 Gy) and not exposed. AUROC values ranged from 0.75 to 0.88. On day 7, ACTN1 and DDB2 expression levels remained significantly upregulated,Atty Ref. 341049: 61-24 WOhighlighting their potential use as candidate biomarkers for the later timepoints after radiation exposure.

[0104] C57BL / 6 mouse in vivo model: recently, we have shown

[0016] that a combination of protein biomarkers (DDB2 and FDXR) with blood cell counts (B- / T-cells) was able to accurately reconstruct dose (R2= 0.738; RMSE = 1.06 Gy and MAE = 0.749 Gy), discriminate between total and partial body irradiation and accurately classify samples as exposed or unexposed with a classification accuracy of 92.2% (AUROC = 0.982). We also determined that mouse sex did not significantly affect biomarker response radiosensitivity and dose reconstruction. FIG. 5 highlights the data from current studies, where we continue to validate the use of biomarkers DDB2 and FDXR to distinguish between unexposed and exposed in vivo in the C57BL / 6 animal model. The data show persistent dose response curves for DDB2 and FDXR are measured at days 1 and 7 post exposure with AUROC values > 0.8.

[0105] RNA expression for radiation biodosimetry: We have pioneered the development of gene expression for radiation biodosimetry [19-21], performing screenings with microarray and RNA-Seq technologies, and validating with real-time RT-PCR. We have further developed signatures for dose reconstruction in human blood irradiated ex vivo

[0022] , and in mice irradiated in vivo

[0023] , In addition, we have studied the effects of specific irradiation scenarios to anticipated radiological or nuclear emergencies, such as low dose rates from fallout [24-26], or ultra-high dose rates and mixed photon-neutron exposures relevant to an improvised nuclear device [27-30], We have also explored the potential impact of factors such as age

[0031] , variations in DNA repair capacity [32,33], and chronic inflammation or immune suppression [30,34] on the performance of our radiation biomarkers.

[0106] In order to develop biomarkers for a proof of principle transcript signature to discriminate exposed from unexposed individuals, we focused on our data from studies of photon exposure to human and NHP ex vivo and in vivo models that used both male and female subjects. We used a recursive feature selection algorithm to select a set of 3 up-regulated genes (CDKN1 A, DDB2, TYMS) and 3 down-regulated genes (CD79B, MYC, EOMES) that performed very well in classifying samples as either exposed to radiation or as unexposed in all datasets. The doses in the different datasets ranged from 1.25 Gy in human patients undergoing total body irradiation (TBI) prior to bone marrow transplant

[0035] , to 7.6 Gy in NHPs exposed to TBI (unpublished results). Human and NHP blood was also exposedAtty Ref. 341049: 61-24 WOin the ex vivo culture model to doses ranging from 2-7 Gy

[0036] , This ex vivo data is from 1 day after exposure, as since showing similar radiation responses in this model at 6, 24, and 48 hours after exposure, our subsequent studies have focused on the day-1 time point. Using the compound covariate predictor, diagonal linear discriminant analysis, or the Bayesian compound covariate predictor to classify samples, the AUROC was 1 for all data sets except the human TBI, which was 0.98-0.99. Greater variability may be expected here due to both the donors’ various disease states and prior chemotherapy, but detection of irradiation is still robust. We are also able to achieve the same AUROC for all groups using the same algorithms with only DDB2, CDKN1A, CD79B, and MYC. Subsequently, we found that a simple ratio of a single up- and down-regulated gene pair (DDB2 and CD79B) gave similar classification results in all data sets. This ratio is shown for the various dose groups in FIGs.6A-6D. Because a large range of times post irradiation was available in our NHP in vivo data set, we plotted the ratios here as a function of time, combining all exposure doses (4, 7.2, 7.6 Gy) FIG. 6D, where the difference between the exposed and unexposed ratio reached a peak at around day 3 after exposure, gradually dropping back towards the baseline levels. Prior experience suggests that lower doses may show a more rapid resolution towards baseline. All groups are distinguished from controls in all data sets with AUROC=1 with the exception of the human TBI (AUROC=0.98; FIG. 6E), and the NHP in vivo at 60 days after irradiation (AUROC=0.83; FIG. 6F).

[0107] Sandwich immunoassay development for protein detection: We identify antibodies pairs and develop a benchtop sandwich immunoassay for the detection of the ACTN1, DDB2, BAX and p53 proteins and at least one housekeeping protein. Although all 6 of the FAST-DOSE biomarkers have shown good dose / time kinetics in vivo over the first week after radiation exposure, our approach is to focus on the top candidates for the early timepoints (up to 3 days) after exposure using the human blood ex vivo model.

[0108] Transition the FAST-DOSE bioassay from the IFC platform to conventional ELISA protocols. FIG. 7 shows data for the detection of DDB2 and BAX expression after the irradiation of human blood ex vivo as well as the persistent upregulation of BAX expression in NHP peripheral blood leukocytes in vivo up to day 5 after total body dose exposure of 2.5 Gy. To begin the transition and integration of the FAST-DOSE biomarkers to the SAMURAI device we use commercially available antibodies and protein standards to develop the sandwich immunoassay. This standard approach has already been successfullyAtty Ref. 341049: 61-24 WOapplied to DDB2 protein and P-tubulin housekeeping protein where antibody pairs have been shown to provide a dose-response (FIG. 8). Protein standards comprise proteins identified as being non-responsive to radiation and include P-tubulin, SDHA, TFRC or P2M. Multiple capture / detection antibodies pairs are first tested in standard multi-well plate format to detect different concentration of recombinant protein. The capture and detection antibodies will be specifically selected to not detect the same epitopes, to be of different species and to be able to be stored at room temperature or 4°C. The pair that provides the highest signal for the lowest concentration of protein (sensitivity) and the minimized signal-to-noise ratio for negative control (specificity) are selected. The best pair(s) are then tested on irradiated peripheral blood mononuclear cells (PBMCs) lysate to assess (1) performance in more complex sample such as multi-protein biological matrix and (2) capacity to inform on irradiation status (exposed vs non-exposed)

[0109] Sample Preparation: Adult healthy samples (> 18 years) are from an equal mix of male and female donors. Whole blood samples from apparently healthy adults are irradiated ex vivo with 0, 3 and 5 Gy X-rays. Samples are placed into culture for 24 h and 48 h after radiation exposure. PBMCs are isolated by Ficoll gradient / SepMate™ tubes. Proteins are extracted from the cell lysate using conventional methods and cell extraction buffers. Total protein levels are measured using BCA kits and quantification of protein biomarker levels are determined using the protein standard provided in each ELISA kit. Success of the assay performance for sample classification exposed or unexposed, are determined by the metric AUROC > 0.8 (p<0.05).

[0110] Irradiation details and dosimetry: Irradiations use an XRAD-320 (Precision X-Ray Inc, Branford, CT). For the irradiations described here, the irradiator is operated at 320 kVp and 12.5 mA and using a custom Thoraeus filter (0.75 mm Sn, 0.25 mm Cu, 1.5 mmAl;HVL4 mm Cu). This filtering hardens the X rays sufficiently that they are comparable in biological effect to137Cs y-rays

[0037] , It also has the advantage of increasing their penetration. Up to 6 blood samples at a time are irradiated at a Source to Surface Distance (SSD) of 55 cm, where the dose variation is <5% across the field. The dose rate is 1 Gy / min.

[0111] Dosimetry is performed daily using a factory- calibrated NIST-traceable 10-6x6 ion chamber (Radcal, Monrovia, CA), placed in the irradiation field and rotated slowly to ensure dose homogeneity. The ion chamber reading is used to calibrate the built-in monitor chamber in the XRAD-320. Periodic verifications of beam uniformity is performed using EBT3 filmAtty Ref. 341049: 61-24 WOplaced under the samples during exposure. Program-wide dosimetry harmonization applies to both sites.

[0112] Using ELISA-based detection methods, we determine optimal antibody pairs. We test several different antibodies (available from an array of commercial vendors) in order to find the antibody pairing with the best sensitivity and selectivity. To better address the detection range for increased protein expression, we have included a 5 Gy dose point in preparation for the full curve (up to 10 Gy) proposed for the dose-response performance studies.

[0113] DNA probes for transcript detection: We develop a benchtop assay for the detection of at least two transcripts based on the binding of DNA probes specific to the targeted RNA and the use of an anti-DNA:RNA hybrid antibody.

[0114] The amplification step is often the limiting factor for the integration of nucleic acid assay in POC devices as it requires advanced thermal control for the different cycles.Therefore, we develop an amplification-free process that uses DNA probes complementary to the RNA targets. The detection is possible through the binding of a gold nanoparticle conjugated-S9.6 monoclonal antibody known for its high affinity and selectivity to DNA:RNA hybrid molecules

[0038] (FIG. 9). The capture of DNA:RNA hybrids by the S9.6 monoclonal antibody does not have sequence specificity, and its molar ratio to DNA:RNA hybrid is documented to be 11-13 under certain conditions, suggesting that a hybrid can bind to more than a dozen antibodies, leading to a significant signal amplification

[0039] , This approach has been recently implemented for the detection of SARS-CoV-2

[0039] and has even been approved by FDA for the simultaneous detection of 13 high-risk HPV subtypes [40,41],

[0115] DNA probes with a length of 30-120 bp are designed in silico using Primer Premier 6.0, based on the RNA genome sequence of our target genes from the National Center for Biotechnology Information (NCBI) GenBank. To the extent possible, we target areas of the genes that are highly conserved between human, NHP, and pig to ease transitions between species, will begin with DDB2 and CD79B as our initial gene pair, with CDKN1A and MYC as the secondary gene pair to be tested. Several DNA probes will be tested for each gene. Although only a capture probe is necessary in theory, at least two probes are selected per gene: one for the capture and at least one for amplification of the detection (FIG. 9). Long probes facilitate the formation of longer hybrids, thereby increasing the sensitivity ofAtty Ref. 341049: 61-24 WOrecognition by S9.6 and thus are prioritized for the detection probes, while shorter probes are selected as capture probes for greater ease of membrane printing. In silico simulation and sequence alignment are also used to prevent cross-binding between the different probes.

[0116] First, in order to assess their specificity of binding, the capture probes are immobilized on multi-well polystyrene plates following standard protocols

[0042] . Whole blood is subjected to differential cell lysis to remove red blood cell material before obtaining an RNA lysate primarily from leukocytes, which are then incubated separately with each of the capture probes. After binding and washing, the RNA is released by denaturation and sequenced to confirm the presence of the target RNA and the absence of non-specific binding.

[0117] Next, the assay is validated using a standard sandwich immunoassay, where the short DNA probes are coated on a plate, RNA lysate is incubated on the plate along with a second probe (long detection DNA probe) for different periods of time (5 to 30 min) at 56°C before incubation with a mouse S9.6 antibody. Detection is performed using an HRP-conjugated anti-mouse antibody. For this stage of the validation, we use lysates prepared from blood exposed to both 0 and 3 Gy and compare the signal from exposed and unexposed samples. Once we determine the final assay protocol, we determine the performance of the assay for sample classification.

[0118] Although we find good cross-platform translation of signatures for dose reconstruction, it is possible that some transcripts will not translate well to the measurement technique being developed here. For this reason, we begin with two pairs of genes, and identify additional genes with similar performance across data sets that could be substituted if needed. It is also possible that the gene ratio approach may need further within-sample normalization, in which case we also develop assays to include, e.g., ACTB and GAPDH for this purpose. The success also depends on the choice of probes that should ensure specific binding to the target. Sequencing is important to assess the probe performance and alternative approaches, such as reverse transcription, can be used to generate a cDNA more stable for sequencing than RNA.

[0119] Common lysis buffer (for RNA and protein): The goal is to select a common cell lysis buffer and protocol that allows simultaneous protein and RNA extraction, and that is compatible with their subsequent detection using immunoassays.Atty Ref. 341049: 61-24 WO

[0120] The composition of cell lysis buffer is largely determined by the subsequent analyses to be performed, and serves mostly to increase the stability of the sample postextraction. RNA lysis buffers are highly denaturant to inhibit endogenous RNases.Conversely, protein lysis buffers are gentler and include protease inhibitors and strong detergent for the solubilization of hydrophobic membrane proteins. Nevertheless, most lysis buffers are sufficient to disrupt the cell and release the contents due to the fragility of the plasma membrane of mammalian cells.

[0121] For this application, the assay is immediately performed after lysis, whereby a cell lysis buffer with low concentration of detergent and denaturant should be sufficient to release protein and RNA. Buffers with different concentrations of SDS, NP40 and / or DOC are tested. The addition of protease and RNAse inhibitors are assessed independently as required. To test the efficiency of lysis, leukocytes are purified by Ficoll gradient, lysed in the various buffers, and assessed immediately. We measure total protein concentration (by microBCA or Bradford) and RNA is isolated using standard protocols and the quantity and quality of RNA will be assessed by Nanodrop and Bioanalyzer. Lysis conditions are tested using both human and NHP blood samples to ensure compatibility with testing in both species.

[0122] The buffer composition that provides the best yields of RNA and protein combined are tested using the developed immunoassays. Samples of human and NHP blood are split in two, with one portion being exposed to a 3 Gy test dose and the second mock-exposed to 0 Gy. After 24 and 48 h, part of each sample is processed by standard methods for conventional assays, and in the remainder, the leukocytes are purified by Ficoll gradient and lysed using the common buffer. The lysate is processed immediately on multi-well plates to detect proteins and transcripts. Because the gene assay requires a heating step (~20 min), and the goal is to perform gene and protein extraction and detection concomitantly and in the same chamber on the VFI platform, protein samples are also tested under these conditions to compare the protein assay performance with or without the pre-heating step. Standard ELISA and qRT-PCR assays are also conducted to compare their classification performance (exposed or unexposed) against that of the common lysis protocol.

[0123] Although very unlikely with immediate use, if a single buffer does not recover both protein and RNA with high yield and quality, or protein detection does not support a heating step, the sample preparation module (SPM) design is adapted to include two separate chambers for independent extraction of proteins and RNA. Because it is known that differentAtty Ref. 341049: 61-24 WOblood cell subtypes express different levels of some transcripts, and may have different radiation responses, it is possible that the selected genes may not perform as well in isolated leukocytes. In this unlikely event, we test the other candidate genes for which we developed assays and move forward with those that perform best in the common lysis protocol.

[0124] Development and optimization of the VFI module: To increase accessibility to POC diagnostic devices, recently, we develop a multiplexed detection of eight Tier 1 biothreat agents using a Vertical Flow paper-based Immunoassay (VFI). Using a miniaturized “syringe-like” device, the sample is pushed through a membrane, which is pre- functionalized with capture antibody, a sandwich assay is then performed (FIG. 10A), and a colorimetric signal is generated by gold nanoparticle (AuNP) to reflect the presence of target antigens (FIG. 10B). Thus, we demonstrate the functionality and advantage of the VFI platform with an improved limit of detection > 80x vs. standard lateral flow immunoassay (LFI) for the detection of the bio-threat pathogen Burkholderia pseudomallei, for example. These results show the ability of VFI to detect microbial antigens or more generally protein markers [43,44], The main advantage of the VFI system over the traditional LFI platform is that it allows for a multiplexed detection of large amounts of biomarkers simultaneously. Plus, the flow path of the VFI is only through the thickness of the porous membrane (between about 100 pm to 150 pm, or about ~ 130 um) vs. ~ 40 mm length in the LFI. This short flow path allows nanoporous membranes to be used for more efficient target capture, as well as larger volumes of sample to be processed than LFI. During DTRA development, a rigid miniaturized silicon support is used that greatly reduces the signal variation across the membrane for better multiplexed biomarker detection and improved sensitivity.

[0125] Further advances are also obtained using novel gold nanostars and device miniaturization [45,46], According to scaling laws of the system, reducing the diameter of the membrane from 10 mm to 2.5 mm, the sample and reagent consumption is reduced by 16x; the active pumping pressure can also be increased 5x to push more sample through the membrane; and higher concentration of AuNP can be used for better assay sensitivity. Based on this miniaturized design, a POC device, or Vertical Integrated Flow Assay System Technology (VeriFAST), is prototyped for mobile military missions. The kit includes an automated syringe pump that can maintain constant flow rate during the assay. The battery powered portable and ruggedized prototype is designed under ISO and FDA compliant Design History File (DHF) system for scalable production.Atty Ref. 341049: 61-24 WO

[0126] We then modify the platform design and create the OMTEST kit (NASA) to respond to the need for POC devices suitable for ease-of-use by individuals everywhere, including in space. The OMTEST kit is a simplified VFI comprising a stacked multilayer of pads and membranes assembled in 3D-printed plastic caps and capsules that does not require any electrical or battery powered instrumentation, and thus, can be performed anywhere outside laboratory / clinical facilities. The sandwich immunoassay is performed at the multiplexed sensing nitrocellulose membrane, which contains the immunoreaction spots. Above the VFI membrane are the functional paper layers, which are responsible for decreasing flow surface area to achieve uniform vertical flow (flow directing pad), decreasing flow rate to increase signal intensity (retarding pad), generating the assay color signal (conjugation pad) and collecting plasma sample (sample pad). These layers are all contained in a 3D printed pad holder placed in a membrane housing that allows contact between the VFI membrane and cotton absorbing pads. The user-friendly device also contains capsules in which are positioned wet pads (assay or washing buffer) that triggers fluid transfer once screwed to the membrane housing and placed in contact with the absorbing pads. The assay buffers and reagents being contained in absorbing pads sealed in caps, this reduces risk of exposure to hazardous chemicals (FIG. 11 A). The kit contains 4 modules comprising the membrane housing protected with a cap, the assay buffer capsule, the washing buffer capsule and a lensmagnifier cap for a direct visualization by naked-eye or using the VeriFAST APP on a smartphone (FIG. 11B).

[0127] As a proof-of-concept, the sandwich immunoassay comprising the multiplex detection of plasma Immunoglobulin M (IgM) and C-reactive protein (CRP). The overall assay completed within 20 minutes (FIG. 12). First, the whole blood is collected from a fingerstick and the plasma separated by capillarity using a plasma separation cartridge. The plasma is then directly loaded on the sample pad and the pad holder placed in the membrane housing. The assay buffer pad-containing capsule is then screwed to the membrane housing and the immunoassay initiated by the contact between the assay buffer pad and absorbing pads that allow fluid transfer by capillarity, independent of gravity or external mechanical forces. After 15 min incubation, the assay buffer capsule is unscrewed and replaced by the washing buffer capsule for 1 min to wash out unspecified signal. Finally, the washing buffer capsule is replaced by the magnifier cap to allow direct membrane visualization. To validate this technology as a robust POC bioassay, the OMTEST kit is tested in extreme conditions during the all- civilian crew flight Inspiration 4 for a 3-day mission onboard of Space XAtty Ref. 341049: 61-24 WODragon capsule in orbit (NASA NNX16AO69A / EXP0006). Interestingly, post-flight examination of the OMTEST kit validated the simplicity of user interface (i.e., use by untrained, non- scientists personnel) and robustness of operations in extreme environments (e.g., microgravity). Jones et al. “Molecular and physiological changes in the SpaceX Inspiration4 civilian crew.” Nature 632, pp. 1155-1164 (2024).

[0128] For the purpose of this Example, the OMTEST test is adapted to ensure simultaneous detection and signal quantification of multiple RNA and protein radiation biomarkers in less than 30 min that can be directly quantify using automatic analysis.

[0129] To directly assess if modifications of the current OMTEST design are required for this example, we test the platform by using total protein lysate from leukocytes and by detecting common intracellular proteins whose antibody pairs for sandwich immunoassay are commercially available. In this condition, the OMTEST is optimized to decrease assay time, decrease membrane background, remove washing steps and improve reproducibility. For example, flow uniformity laterally across the printed membrane is critical for our VFI platform as it relies on spatial multiplexing. Darcy's law states that in fully-wetted porous media, volumetric flow-rate is inversely proportional to flow distance, meaning that the larger the cross-sectional area of the multiplexed VFI the more non-uniform the vertical flow will be as the fluid spreads both laterally and vertically to the edges of the device

[0047] , Therefore, we test the implementation of a flow diffuser, added to the pad holder, that contains multiple concentric barriers to enable an even distribution of flow rates across the sensing membrane. In parallel, different material composition, thickness and porosity of the membranes and pads are tested for fluid control to obtain the best ratio between signal intensity and flow rate.Because the non-purified lysis of leukocytes may generate important cellular debris, we also consider adding membrane filters to clear large particles off the conjugation pad and VFI membrane. A washing step and wash buffer composition is also assessed and optimized to maximize the signal-to-noise ratio for an improved mobile-phone acquisition and software-assisted analysis. Finally, as the OMTEST has been initially designed for use in microgravity, other approaches for fluid intake, such as direct loading, are tested and signal intensity compared with the current wetted pads method.

[0130] Success depends on the robustness and efficiency of the sandwich immunoassay. Although the use of commercially available validated antibody pairs minimizes the risk, if we encounter an issue integrating the new assay into the VFI, we can use assays havingAtty Ref. 341049: 61-24 WOdemonstrated success (LcrV, Fl, LPS, CRP, IgM, etc.). In this case, the recombinant proteins are directly spiked in the total protein leukocyte lysate.

[0131] Membrane printing: We develop a membrane printing protocol to coat antibodies, DNA probes and controls on a multiplex layout and compatible with the instant POC device. Simple VFI membranes are fabricated using nitrocellulose membrane sheets (0.2 pm pore size), which have been prepared into target membranes on a bench top CO2 laser cutter. These target membranes have circular discs (6 mm diameter) cut into a 6 x 5 design with fiducial markers for targeting the dispensing locations during microarray printing. Control and test capture antibodies (cAbs) and DNA probes are dispensed at working concentrations capable of saturating the nitrocellulose membrane. In a clean room environment, a NanoPlotter NP2.1 is used for non-contact piezoelectric microarray dispensing of these cAbs onto the circular discs of each target nitrocellulose membrane. Spot-Front-End software is utilized to coordinate a spotting plan for use in the Nano-plotter Controller software, to dispense a pattern of the antibody microarray onto the center of each circular disc (ranging up to 20 spots). The test cAbs are dispensed in a specified number of droplets per spot at their respective working concentrations to produce maximum sensitivity based on individual assay optimizations. Control cAbs are dispensed in a specified number of droplets per spot at their respective working concentrations to produce optimal signal intensity for image analysis purposes. The immunoassay membranes are then stored in a humidity and light controlled environment until housing assembly. The addition of barcodes or QR codes directly on the membranes are also optionally provided in order to further improve tracking record of the membrane.

[0132] Due to potential exposure of the immunoassay membrane to high temperatures during nucleic acid assay, the use of protein and sugar may be employed to improve antibody stability if required. Additionally, desiccant film may be used within the membrane housing to mitigate humidity exposure from stored liquid reagents

[0133] Image acquisition, analysis and software algorithm development: We construct an apparatus allowing VFI membrane picture acquisition and automatic analysis for unbiased result interpretation, including via a digital imager, camera or the like. To satisfy FDA requirements for data analysis and interpretation of POC tests, the VFI membrane can automatically analyzed. In this aspect, we provide an apparatus formed from a single magnifier lens or magnifying cap 1310 in a lens adapter 1320 (FIG. 13A) to position the VFIAtty Ref. 341049: 61-24 WOmembrane (annotated as part of “membrane housing”) appropriately for image acquisition 1340 (FIG. 13B) using a standard smartphone 1330. The single magnifier lens design is not only much more compact than a multiple- lens design but also offers a larger field of view

[0048] , A compact battery powered LED light ring can be used to illuminate the membrane for reproducible results and automatic analysis with software. The mobile phone software is developed together with Promenade Software, Inc (Irvine, CA). The software has the functions of 1) taking the VFI membrane image, 2) image analysis, 3) reporting the results, 4) saving the results, 5) sending the results to a secure cloud location, and 6) tracking each patient’s report by his / her specific patient ID. Based on the existing VFI data analysis software developed in Lab VIEW and VeriFAST™ App (Fig. 13B), we first modify the algorithm and user-interface of the smartphone app to produce an image for analysis of the proteo-transcriptomic signals for informing triage application and transfer of data for POC requirements. The App can provide a 48-bit image for analysis and be compatible with USG-approved smartphones (e.g., iOS products). The algorithm performs an initial cropping of the image acquired by the smartphone. Initially, only the center 1600x1600 part of the image is sent to the algorithm in case both the xand y dimensions are greater than 1600. This is mostly done for display purposes of the results (the circles and numbers would look very small on the full image) and to limit the circle search space to the relevant part of the image. The next step is pre-processing, which involves a slight blurring so the circle detection can work on the more obvious edges in the image with less distraction by small noise. After slight blurring for noise removal there is a sharpening step to improve circle detection on blurry images. The sharpening method takes the weighted sum of the input image and a slightly blurred version of the input image. Then circles are detected using the Hough Gradient Method for detection of each circle to be evaluated for distances to the reference pattern. The signal dot’s locations can be calculated by creating a grid with the knowledge of where 2 specific control dots are located. If a circle is found close to the expected location on the grid, the coordinates of this circle are used instead of the grid coordinate, otherwise the grid location is used. For every biomarker dot, a fixed radius is used for signal extraction. As instructed, this is 20% of the distance between the dots on the grid. Since this radius is on the smaller side, a circle location needs to be less than twice this radius off from the grid location to be used as biomarker location. The background dot signal can be sampled at 4 locations around the biomarker dots. The radius of the background circles is the same as for the biomarker dots. The sample locations are typically at 45-degree angles from the regular grid lines and are exactly in between 2 dots on the diagonal. The background with the lowest standard deviationAtty Ref. 341049: 61-24 WOis used to compare against the biomarker signal. Finally, positive / negative detection can follow the formula: positive = DETECTED TIMES STDDEV x B ackground StdDev < MeanBackground - Mean Signal - DETECT THRESHOLD INCREASE.

[0134] Sample Preparation Module (SPM): The biodosimetry biomarkers for discrimination of unexposed individuals from radiation exposed individuals comprises intracellular leukocyte proteins and genes. Therefore, there is a need for a POC sample preparation to provide the required material to the assay. To be compatible with the OMTEST, the sample preparation is integrated in a simple module based on the cap / tube configuration that fits the pre-existing modules of the current OMTEST, and can together form a SAMURAI kit or assembled SAMURAI device.

[0135] The SPM can be first screwed on the membrane housing (FIG. 14). Then, whole blood can be collected by fingerstick and loaded in an FDA-approved Minivette® (Sarstedt) that is capable of insertion on the side of the sample container of the SPM to dispense whole blood to the chamber (FIG. 14 - top left panel). Whole blood is then mixed with a red blood cell lysis buffer that will be safely released by pressing down the top container to thereby cause piercing by a piercing disk (FIG 14, step 1-2). After an incubation step, the device is inverted to collect the supernatant and unwanted cells in the central reservoir of the top container (FIG. 14, step 3). The leukocytes are retained by a leukocyte-specific antibody, such as anti-CD45, coated on the wall on the sample chamber. The top container is then pressed down a second time to seal the central reservoir and pierce the lateral reservoirs to release the leukocyte lysis buffer (FIG. 14, step 4). The device is inverted again to return to its initial position where an incubation step facilitates leukocyte lysis (FIG. 14, step 5). Then, a heating pad (e.g., thermal controller 1805) will be placed around the sample chamber and the device placed in an insulated container for a last incubation step required for optimal hybridization between target RNA and DNA probes (FIG. 14, step 6). Finally, the whole SPM is pressed down to pierce its bottom lidding film and release sample to the VFI membrane (FIG. 14, step 7).

[0136] The SPM can be made using 3D printing for parts and design iteration. The rapid turnaround time to produce a physical model will allow engineering to have assessment of the mechanical functions, fitting, and assembly within days. Urethane casting bridges the development between 3D print prototyping and injection molding. The process is similar to injection molding but with room temperature materials, soft molds, and a CNC masterAtty Ref. 341049: 61-24 WOpattern. The casting is a production level copy of the master in durable plastic but 1 / 10 the price and in a 20 to 500 pieces range. Soft Urethane casting is assessed for its assembly, mechanical properties, optical properties, and thermal properties.

[0137] Conventional 3D prints can suffer from an about 0.05mm surface roughness, which prevents smooth movement of sliding mechanical parts. However, the initial phase allows a low- cost option to evaluate the ergonomics, aesthetics, design for manufacturing and usability of the device so that it will closely simulate the final product. Particularly relevant is ensuring the device is sufficiently robust to withstand inadvertent impact forces associated with transport, handling, and use.

[0138] Performance evaluation with biological matrix to optimize the workflow to obtain non-degraded RNA and / or protein from leukocytes using the SPM: An approximate volume of 100 pL of whole blood is loaded in the SPM sample container using, for example, a Minivette® device or other whole blood sample holder. First, red blood cell lysis efficiency is determined under different conditions. These conditions includes the testing of different incubation time (5-15 min), volume (500 to 1000 pL), and shaking. Red blood cell lysis buffer will be released by piercing the central chamber of the SPM top container. Efficiency of the red blood cell lysis is assessed by collecting the lysate after piercing the bottom lidding film and measuring the absorbance at 404 nm. Lysis is considered efficient if absorbance is comprised between 1.2 and 1.6. In parallel, the internal wall of the SPM sample container can be coated with anti-CD3 and anti-CD19 antibodies following our standard protocols using carbonate / bicarbonate buffer. Efficiency of the coating is assessed by loading a sample of a known leukocyte number and by counting the number of PBMCs after incubation. A ratio of initial leukocyte number / recovered leukocyte number > 10 is considered acceptable for efficient capture and subsequent assays. Finally, we assess leukocyte lysis efficiency.Following red blood cell lysis and leukocyte capture according to the previous set parameters, cell lysis buffer for RNA and protein is / are released by piercing the lateral reservoirs of the top container. Different time of incubation and shaking conditions are tested. Lysis efficiency is tested by quantifying protein using BCA assay and RNA using nanodrop. This step helps to determine the amount of genetic material and protein that can be extracted from a certain volume of whole blood using the SPM in order to define the minimal starting sample volume required for the instant assay. In addition, qPCR and ELISA of housekeeping genes andAtty Ref. 341049: 61-24 WOproteins, respectively, are performed to assess sample quality and ability to bind antibody. Ultimately, a combined cell lysis buffer for RNA and protein is tested.

[0139] The capture of T and B-cells is an important step for the success of the SPM.Although the coating of antibodies on plastic surface is well-established, in case of low capture, anti-CD3 and anti-CD19 magnetic beads may be used. This involves the use of a magnet that may be added around the sample container without any major design changes. In addition, viscosity after leukocyte lysis can also alter RNA or protein recovery and especially, diffusion through the membrane. If a high viscosity is observed, addition of a larger volume of buffer can decrease the viscosity. This will not dilute the target as the entire sample will pass through the membrane as the absorbing pad in the membrane housing can be adapted to collect the desired volume.

[0140] SPM catalytic heating system: We provide a controlled thermal system able to provide the required temperature during the required time within the SPM to satisfy DNA-RNA hybridization, if necessary, without degrading proteins. We first test commercially available single use instant hot packs (or chemical heating pad technology) as the heat source for the annealing process. The first step when running the kit is to activate the hot pack and place in the metallic foil bubble envelope for pre-heating. Hot pack should reach the target temperature (56°C) within 10-15 minutes. During this time, the user begins the sample preparation process with the device. At the point when the sample needs to be heated, the hot pack is removed from the envelope and wrapped around the device. The hot pack is secured with an elastic band then placed back into the foil envelope and should sustain the target temperature for at least 20 minutes.

[0141] Temperature ramping speed and temperature targets are evaluated with thermocouple probe wires placed inside the sample chamber and outside the device. Realtime temperature data is gathered to verify hot pack thermal transfer through the device material and into the sample. The detailed investigation phase samples various hot pack brands for a series of performance and consistency tests. Stability at the target temperature and ramp rate is the key factor in selecting the optimal heat source for the kit. Additional stick-on temperature labels could also be calibrated to indicate the appropriate range of temperature for guiding the user. Once engineering design demonstrated functional operation of the heating system, molecular testing is performed to assess biological relevance. For this, isothermal amplification using a well-established protocol is performedAtty Ref. 341049: 61-24 WOwithin the device. Sample mix is prepared on the benchtop and directly loaded within the device. At the end of the reaction, product is collected and run on agarose gel electrophoresis. Size and signal intensity of the amplicons is compared with samples amplified isothermally using a conventional thermocycler. Finally, leukocyte lysate is directly loaded in the SPM and heated following the determined protocol. Although protein denaturation is unlikely to occur at this temperature, if it does occur, denaturation is perfectly compatible for sandwich immunoassay. Protein quality is assessed by performing standard ELISA. Mitigation plan. Additional heating options are available if the target temperature is not met with the hot packs. One method uses the same chemical components in hot packs but in a capsule form. The capsule dimensions would allow it to fit inside the chamber and closer to the sample. Additional mechanical movements of the device can be implemented into the design to activate the reaction in the capsule. Composition of the chemical heat mixture can be evaluated and optimized for temperature constancy within the operating range. Another design option is to incorporate an outer chamber surrounding the sample chamber. This outer chamber would house the chemical heating components. This method will also require additional mechanical movements in the device to activate the heat source. The last option is to investigate heated films powered by a miniature battery cell. On-demand heating can be achieved with this configuration but at higher costs per device.

[0142] Our previous work with biothreat pathogens showed that integration of protein immunoassay is compatible with VFI technology [43,45,46], Importantly, we also showed successful integration of a nucleic acid assay. Using labeled primers during amplification and a multiplex membrane, our results showed that the nucleic acid VFI can simultaneously detect two of our target radiation biomarker genes, CDKN1 A and DDB2, as well as one housekeeping gene MRPS5 (Fig. 15 - panel A). The assay demonstrated good linearity (panel B) and precision with an inter- and intra-assay coefficient of variance < 15% and < 10%, respectively (panel C). Moreover, the assay showed its ability to discriminate nonexposed controls from radiation-exposed samples with an Area Under the Curve (AUC) of 0.905 (95% CI = [0.77-1.00]). After defining the optimal threshold, the assay showed an overall sensitivity of 100% and specificity of 70% (panel D). Interestingly, the gene combination also showed a dose-dependent response for 0, 1 and 2 Gy, similar to data obtained by real-time PCR benchmark (panels E-F). These results show the compatibility of VFI for gene assay, especially for radiation screening.Atty Ref. 341049: 61-24 WO

[0143] In addition, during the COVID-19 pandemic, we successfully adapted the OMTEST to accommodate multiple assay chemistries including the PCR- based gene detection of the viral infection, but also antibodies indicative of the immunity level of an individual. We thus demonstrated the OMTEST capacity to detect both gene (SARS-CoV-2 N gene to detect viral particles) and protein (human anti-S protein IgG to assess immune response to SARS- CoV-2). We established preliminary limit-of-detection of 10 copies / pL for SARS-CoV-2 viral particles and about 12.5 ng / reaction for anti-S SARS-CoV-2 protein IgG. More interestingly, we also demonstrated that both N gene and anti-S protein IgG spiked in artificial saliva could be identified on the same membrane, showing the capacity of the system for multiplex detection of both genes and proteins (FIG. 16).

[0144] Following a similar approach, we integrate the protein and gene immunoassay developed above in the SAMURAI kit, and achieve the following: Integration of the benchtop protein immunoassay in the VFI module

[0145] The goal is to obtain a signal intensity proportional to the concentration of the loaded protein on the VFI membrane of the SAMURAI POC device.

[0146] The capture antibodies of all proteins identified are printed on the membrane.Proteins are first assessed individually. Therefore, the conjugation pad is loaded with the appropriate detection antibody and a secondary antibody, if required. Recombinant protein, at different concentrations, are spiked in an optimal buffer that is directly loaded into the VFI detection module. Successful completion of the immunoassay integration will be assessed by the presence of a dose response based on signal intensity and specificity (i.e. absence of nonspecific binding on the other membrane immunospots). At this stage, limit of detection and sensitivity of the assay will also be determined. If successful, a multiplex assay, by spiking two or all recombinant proteins at once in the buffer and by coating the conjugation pad with two or all detection antibodies will be performed in a second step. This step will assess the absence of competitive interaction, non- specific binding or hindrance by comparing signal intensity obtained during the single plex experiment for the same concentration. Finally, a third step assesses the detection capacity of the VFI using biological matrix. Thus, the assay is performed by loading directly leukocyte lysate collected following the same protocol as defined above using the appropriate cell lysis buffer. In this step, the conjugation pad is coated with only one detection antibody in order to assess specificity and background. ConcentrationAtty Ref. 341049: 61-24 WOof protein in the sample is assessed by standard ELISA and compared to VFI signal intensity to determine sensitivity and limit of detection of the SAMURAI kit in biological matrix

[0147] If signal is faint and / or shows nonspecific binding not seen during benchtop development, several standard strategies are available: optimization of capture antibody concentration on VFI membrane and / or conjugation pad, direct vs indirect detection (secondary antibody or detection antibody directly labelled with gold nanoparticles). If the background is too high, a washing step is considered using a washing cap module.

[0148] Integration of the benchtop RNA assay in the VFI module to detect targeted genes on the VFI membrane of the SAMURAI device. The capture DNA probes of all genes identified are printed on the membrane following the protocol. Genes are first assessed individually by coating the conjugation pad with only the detection probes of one gene. The S9.6 DNARNA hybrid antibody is conjugated with gold nanoparticles to have an OD > 10 and then loaded on the conjugation pad. Leukocyte lysate, prepared as described, is directly loaded in the VFI detection module. Signal should demonstrate high specificity by only being above background on target spots. To assess assay sensitivity, each gene is amplified, cloned into plasmid and copy number determined by absolute quantification. Different copy number is then loaded in the biological matrix and dose response is evaluated for each gene to determine limit of detection. A last step involves a multiplex assay where all genes are loaded together at different concentrations to assess the absence of non-specific binding, if signal is faint for high concentrations, addition of detection probes are considered to increase the number of binding sites for the S9.6 antibody. Although we do not expect non-specific binding due to the in silico simulation and assessment, hindrance on the conjugation pad due to a high concentration of the DNA probe and / or detection antibody might increase the background. In this case, optimization is performed mainly by testing different protocols for washing, in addition to supplemental optimization of the conjugation pad.

[0149] Combination of the sample preparation with the VFI module to obtain a protein and / or gene signal on the VFI Module from whole blood processed using the SPM. The complete workflow of the SAMURAI POC device is assessed by integrating the SPM step using whole blood with the VFI module, where signal is captured and analyzed with the App. Whole blood is loaded within the SPM and processed (red blood cells lysis, anti-CD3 / CD19 binding, leukocyte binding and heating step) following the same approach as previously described. Signal intensity and assay efficiency is evaluated following the same approach asAtty Ref. 341049: 61-24 WOpreviously described. First, gene and protein assays are assessed independently by only coating the conjugation pad with either detection antibodies or DNA probes with S9.6 DNA:RNA antibody. Then, the final step comprises performing the combined assay following the SAMURAI workflow (FIG. 17).

[0150] Steps summarized in the POC device of FIG. 17 and include: (1) Dispense fingerstick-collected blood sample in device. (2) Close opening by turning latch until plug aligns with hole opening. (3) Press Sample Container down to seal opening. (4) Press Top Container down to pierce film in center chamber. Rotate Top Container 360 degrees to cut film. Shake device to transfer all RBC Lysis Buffer to the Sample Chamber. (5) Overturn device to transfer blood and buffer material to center well. (6) Rotate Top Container 45 degrees. Align arrows on Sample Container and Top Container. Press Sample Container down to plug center chamber with O-ring. Overturn device upright and rotate Top Container 360 degrees to cut outer well film. (7) Transfer device to insulated thermal envelope and heat for 20 minutes. (8) Remove from envelope and Press Sample Container down while turning 180 degrees. Film is cut and sample flows to membrane filter. (9) Turn Membrane Housing 25 degrees and align arrows with Sample Container. (10) Press Sample Container into Membrane Housing. (11) Pull Sample Container up while turning 180 degrees to the starting position. Continue to pull Sample Container from Membrane Housing until completely removed. (12) Snap Lens Cap on Membrane Housing. Lens Cap also serves as a lid to prevent sample residue from touching camera. (13) Thread lens on adapter until VFI membrane is in focus. (14) Capture image on App.

[0151] The SPM is combined with the VFI module to assess the SAMURAI kit capacity to deliver a protein and / or gene signal. SPM-processed whole cell lysate is transferred to the VFI module. Although we do not expect major issues with the assays themselves, we may observe a decreased signal intensity that could be due to the sample preparation, with, for example, the presence of large cellular debris that could obstruct the membranes and pads and alter flow rate. In this case, alternate solutions such as an increase of cell lysis volume or the addition of membrane filters to capture debris in the pad holder can be implemented.

[0152] Software App performance and testing from a picture taken directly from a processed membrane with the lens adapter and related lens components. After the algorithm development, a basic workflow and camera with frame is established for verification. User interfaces are verified by: Selection of Image to Process— Detect reference pattern— CalculateAtty Ref. 341049: 61-24 WOwhich dots pass threshold— Find best background for each dot— Display processed image— Result Screen— Correct image rotation for camera pictures— Initial optimization of iPhone Camera settings. The user will install TestFlight from the Apple App Store to proceed installing the Samurai App on the phone. Images for the can also be downloaded to Mac or Windows-based computers for accessing the original images, processed images and the CSV files. Verification is performed per IEC 62304 lifecycle processes and tested against a library of test images representatives of multiple POC conditions (i.e., different moisture conditions (dry to wet) and illumination settings (bright to dark)). These data are compared with standard analysis using computer scanner and image analysis software (e.g., ImageJ).

[0153] Biodosimetry performance of the benchtop gene and protein assays: Determination of assay dose response and limits of detection in non-human primate (NHP) blood irradiated ex vivo) to extend the benchtop assays developed for the human blood ex vivo model for a NHP model, again using blood irradiated ex vivo, and to test the performance of the assay in classifying samples as exposed or unexposed across a range of doses. We also determine the limits of detection for the protein and transcript assays.

[0154] We begin with a pilot study using NHP blood samples exposed to 0 or 3 Gy and processed 24 and 48 h after exposure to test the RNA capture / detection probes and ELISA kits. For the protein assays, we continue to optimize and develop the protein curves. NHP blood samples are purchased from a commercial vendor. Whole blood samples for each dose are split into two and samples prepared according to the blood lysis protocol described previously and by conventional lymphocyte enrichment methods using SepMate™ PBMC isolation tubes.

[0155] For the transcript assays, an aliquot of each blood sample is processed for RNA isolation using standard protocols, with another aliquot being lysed following the protocol previously described. The benchtop transcript assay is performed, with qRT-PCR being conducted on the RNA isolated from the same samples as a positive control. The specificity of transcript capture is again determined by sequencing the captured material. If insufficient capture or non-specific binding is detected, we can re-design probes to improve performance and re-test.

[0156] For the dose-response study, we initially use blood from 5 male and 5 female NHPs, split into aliquots and exposed to 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, or 10 Gy. At 24 and 48Atty Ref. 341049: 61-24 WOh after exposure, blinded samples are lysed and analyzed using the benchtop protein and transcript assays, and classified as either exposed or non-exposed. After unblinding of the samples, the performance of both the protein and transcript classifier are compared by ROC analysis and determining the AUC for each dose independently. The results of the protein and transcript assays are also combined as a single classifier to compare performance. We designate the lower limit of detection as the dose, below which the AUC drops below 0.8. We also determine the behavior of the assays across the dose range tested and determine if very high doses can be reliably detected.

[0157] A second dose response study is then be conducted using blood from 5 male and 5 female NHPs to confirm the range of the assay. This study uses unexposed controls, two doses near the lower limit of the assay as determined in the first experiment, and two high doses. The samples are processed in the same way, with additional validation using qRT-PCR.

[0158] Although our proteins and transcripts have been selected as having the same performance in both human and NHP models, it is possible that some may not translate to the new assay platform. Our initial plan in this case is to redesign and re-test the capture oligos or antibodies, but we also have additional candidate biomarkers that have shown similar performance in previous measurement platforms that could be developed to support NHP testing if needed. We expect this activity to be low risk based on the preliminary data for protein and gene transcripts that have shown high conservation of radiation response across species and translated well from the human to the NHP model.

[0159] Determination of assay dose response and limits of detection in human blood irradiated ex vivo to determine the performance of the assays in human blood irradiated ex vivo across a range of doses. We will initially use blood from 5 male and 5 female donors, split into aliquots and exposed to 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, or 10 Gy. At 24 and 48 h after exposure, blinded samples will be lysed and analyzed using the benchtop protein and transcript assays, and classified as either exposed or non-exposed. After unblinding of the samples, the performance of both the protein and transcript classifier will be compared by AUROC analysis, and determined for each dose independently. The results of the protein and transcript assays will also be combined as a single classifier to compare performance. We will designate the lower limit of detection as the dose below which the AUROC drops below 0.8.Atty Ref. 341049: 61-24 WOWe will also determine the behavior of the assays across the dose range tested and determine if very high doses can be reliably detected.

[0160] A second dose response study will be conducted using blood from 5 male and 5 female donors to confirm the range of the assay. This study will use unexposed controls, two doses near the lower limit of the assay as determined in the first experiment, and two high doses. The samples will be processed as above, with additional validation using qRT-PCR.

[0161] Testing and validation of the benchtop assays in pig model: Development of conventional RNA and protein assays for the pig model using ex vivo irradiated blood to transition the human / NHP benchtop assays to a porcine model, as a bridge to in vivo testing is a large animal model with more stable availability than NHPs.

[0162] The use of miniature swine as a nonrodent species in safety assessment has continued to expand for over a decade, and they are becoming routinely used in toxicology and in pharmacology as well as a model for human diseases

[0049] , The minipig is also emerging as an alternative non-rodent model and offers a useful alternative to NHP and canines to be used for radiation countermeasure testing under the FDA animal rule [50,51], Studies have shown that minipigs share many physiological similarities with humans while also offering several financial, breeding, and handling advantages [52,53], Studies by Moroni and colleagues [50,51] have shown that the pathophysiology of ARS in the Gottingen minipig is similar to that observed in humans, NHP, and dogs in terms of hematological dynamics and the importance of thrombocyte counts. Recently, the team at Lovelace Biomedical presented data on the development of hematopoietic- ARS in Gottingen and Sinclair minipigs

[0054] , Although both minipig strains exhibited similar prototypical H-ARS characteristics, it was noted that all observations correlated with dose more closely in the Sinclairs than in Gbttingens. Sinclair minipigs have been shown to have 100% survival 45 days after the highest dose administered (2.3 Gy) while only 25% of Gottingen minipigs survived at the same dose

[0055] , The fact that the minipig model allows for multiple large volume sampling for extended periods of time following irradiation, makes minipigs a suitable model for development and testing of dosimetry assays and devices and medical countermeasures for radiation exposure. To this end, we propose to use the Sinclair minipig model.

[0163] We begin by testing our assays in this porcine model using conventional assays to confirm the expected radiation response of our target genes and proteins. This is an importantAtty Ref. 341049: 61-24 WOstep, as although most targets respond similarly across species, some differences have been observed in between humans and mouse

[0022] and even between humans and NHP [36,56], We obtain commercial blood samples from Sinclair miniature swine, split them, and expose them to 0, 3, or 5 Gy. The blood is cultured for 24 and 48h and then processed using conventional protocols for protein and RNA recovery. The material is then tested by ELISA and qRT-PCR. In cases where reported cross-reactivity or sequence homology suggests the antibodies or qRT-PCR assays used in the human / NHP studies are likely to work in pig, these are tested first, with pig- specific assays being used where necessary. We test our full range of candidate protein and transcript biomarkers. Their performance in classifying the blinded samples as exposed or un-exposed is compared by ROC analysis, and the best biomarker combinations selected for further development of the pig assays.

[0164] Commercial ELISA antibody kits (BAX, p53, DDB2) and pre-designed TaqMan assays (DDB2, CD79B, CDKN1A, MYC, EOMES) are available with porcine species reactivity. However, it is possible that one or more of our top biomarkers from the human / NHP studies may not respond to irradiation the same way in the pig model. Against this possibility we will develop and test pig standard assays for candidate biomarkers in addition to our top human biomarkers, replacing biomarkers if needed.

[0165] Testing the integrated benchtop RNA and protein assays for the minipig model using ex vivo irradiated blood to transition the benchtop assays developed for the human ex vivo model, with any modifications indicated, to the miniature swine model, again using blood irradiated ex vivo, and to test the performance of the assay in classifying samples as exposed or unexposed across a range of doses. We also determine the limits of detection for the protein and transcript assays. We begin with a pilot study using Sinclair minipig blood samples exposed ex vivo to 0 or 3 Gy and processed 24 and 48 h after exposure to test the ELISA kits and RNA capture / detection probes. It may be necessary to redesign probes or test additional ELISA antibodies to ensure the test functions as expected for the pig model. We test the full set of potential biomarkers. For the benchtop protein and transcript assays, cell lysates and samples are prepared as described, respectively. The specificity of transcript capture is determined by sequencing the captured material as. If insufficient capture or nonspecific binding is detected, we can re-design probes to improve performance and re-test. We then proceed to signal detection.Atty Ref. 341049: 61-24 WO

[0166] For the dose-response study, we initially use blood from 5 male and 5 female animals, split into aliquots and exposed to 0, 0.25, 0.5, 1, 1.5, 2, 3, 5, 8 Gy. At 24 and 48 h after exposure, blinded samples are lysed and analyzed using the benchtop protein and transcript assays, and classified as either exposed or non-exposed. After unblinding of the samples, the performance of both the protein and transcript classifiers are compared by ROC analysis and the AUC determined independently for each dose. The results of the protein and transcript assays are combined as a single classifier to compare performance. We designate the lower limit of detection as the dose below which the AUC drops below 0.8. We also determine the behavior of the assays across the dose range tested and determine if very high doses can be reliably detected in this model.

[0167] A second dose response study is conducted using blood from 5 male and 5 female animals to confirm the range of the assay. This study uses unexposed controls, two doses near the lower limit of the assay as determined in the first experiment, and two high doses. The samples are processed as above, with additional validation using standard ELISA and qRT-PCR measurements on the same samples.

[0168] We test multiple potential biomarkers in case some do not translate well to the benchtop assays. If our preferred human / NHP biomarkers do not work well in the pig model, we replace them with the best-performing ones to enable proof of principle in the in vivo pig model. The success of this task also depends on the choice of probes that ensure specific binding to the target. Sequencing will be important to assess the probe performance and alternative approaches, such as reverse transcription, could be used to generate a cDNA that is more stable for sequencing than RNA.

[0169] In vivo testing of the benchtop radiation detection assays integrated biodosimetry approach in a minipig model to perform an in vivo proof-of-principle pilot study in a large animal model, testing the capability of our protein and RNA-based benchtop assay, to distinguish between exposed and unexposed blood samples collected from the Sinclair minipig.

[0170] Sinclair minipigs are purchased from Sinclair Bioresources (Columbia, MO - see quote) and exposed to a total body dose of 2.5 Gy. This dose was selected based on a recent study

[0054] that compared models of hematopoietic-acute radiation syndrome in Gottingen and Sinclair minipigs, where it was shown that the lethal dose for 50% of the population over theAtty Ref. 341049: 61-24 WOcourse of 45 days (LD50 / 45) with ‘field’ supportive care (primarily antibiotics and hydration support) was 1.89 and 2.53 Gy for Gottingens and Sinclairs, respectively. Before the irradiation, we record the animal body weights and peripheral blood cell counts (CBC with WBC differential) and blood samples are obtained for protein and gene biomarker measurements. The minipigs (male, aged 4 to 6 months) are irradiated with a total body dose of 2.5 Gy, using a 6-MV photon beam generated from a clinical Varian Ethos Medical Linear Accelerator (Varian, A Siemens Healthineers Company). Animals are sedated for irradiation as per Columbia ICM protocols (see letter of support from Dr. Romanov at the Columbia ICM). Animals are weighed and blood will be collected on days 1-7, 14, 21 and 28 after radiation exposure, and processed for cell counts, conventional ELISA and qRT-PCR, and for the benchtop measurement of RNA and protein. The performance of the conventional assays in classifying the samples as exposed or un-exposed is determined by ROC analysis and the AUROC will be compared to that generated using Task 6-2 protocols. Euthanasia and necropsy is scheduled for day 28 after radiation exposure, with animals euthanized early if they reach euthanasia criteria.

[0171] Irradiation and dosimetry: Varian’s Ethos is a closed gantry, wide bore medical linear accelerator (LINAC) developed to facilitate efficient online adaptive radiotherapy (onART). Prior to irradiation, the instrument output will be verified for dosimetry with an acceptance criterion less than 2%. Based on our previous experience with the irradiation of NHPs, we do not anticipate any problems with the irradiation of the minipigs and veterinary care.

[0172] Performance characteristics of the SAMURAI kit: Performance testing of the SAMURAI kit on irradiated samples to assess the capacity of the SAMURAI kit to distinguish exposed from unexposed whole blood samples. Blood from 10 male and 10 female donors is aliquoted and exposed to the two high and two low doses to define the range of detection for the benchtop assays. For each donor, an aliquot is kept as an unexposed control. The samples are incubated for 24 and 48h, blinded, and then loaded onto the SPM, and processed through the full workflow to detect both protein and transcript signals using the integrated VFI module. Signal intensity is calculated, and each sample classified as exposed or unexposed. The performance of the integrated SAMURAI for detection of exposed samples is assessed via ROC analysis, with AUROC >0.8 considered successful performance.Atty Ref. 341049: 61-24 WO

[0173] Half of the samples are also processed using standard protocols and subjected to ELISA measurement of protein biomarkers and qRT-PCR measurement of transcript biomarkers. The classification of these samples with standard measurement techniques is also assessed by ROC analysis, and the results compared with those of the SAMURAI measurements as additional validation.

[0174] In order to evaluate the SAMURAI kit performance appropriately, and to start collecting FDA- relevant data, this approach is performed in parallel by different users at independent sites. If the limits of detection cannot be accurately classified by the SAMURAI (AUROC<0.8), we test additional doses to determine the range where the integrated assay is useful.

[0175] Stability and storage condition to assess a basal shelflife of the SAMURAI kit when stored in normal vs. challenging conditions encountered during operational use. The test is expected to have demonstrated ability to discriminate 0 Gy from irradiated samples.Therefore, these results will be used to compare with new results obtained from the SAMURAI kit that will have previously been challenged by several environmental factors. This will have the objective to identify the reagents and hardware parts that could contribute to shorten the shelf life of the platform and that should be considered for remanufacturing. We expect the SAMURAI kit to have best stability in refrigerated conditions. However, the SAMURAI kit is intended to be deployed on field as a POC screening device after a mass casualty radiological incident. In such a situation, temporary medical facilities will be immediately set up with limited operational capabilities (e.g., lack of power supply, materials, etc.) during the early phase of the response. Ideally, the SAMURAI kit should be then sent without the need for specific storage conditions. We thus also assess the stability of the SAMURAI kit at room temperature for a period up to 1 week. Our results during the Inspiration4 mission showed us the importance of humidity control for the storage. The SAMURAI kit can also be challenged with different humidity levels (in presence of desiccant) recapitulating the humidity range observed in the US (25-95% humidity).

[0176] Most of the reagents will be coated and dried on membrane supports (VFI membrane or conjugation pad). The SPM will contain cell lysis buffers, with demonstrated high stability in laboratory settings, as well as DNA probes, also known to be a robust compound. Consequently, we are confident in the stability of the platform but in case of highly decreased shelflife in challenging conditions likely to be encountered in operationalAtty Ref. 341049: 61-24 WOuse, improvement can be achieved by modifying the protocols for membrane coating, lyophilizing reagents if possible, or slightly adapting device design.

[0177] App validation and cloud-based data testing to evaluate the capacity of the software App to distinguish biodosimetry status from membrane processed with the complete SAMURAI workflow and explore its cloud-based server functionality. The final validation study protocols are established for multi-users at multiple sites using beta-prototypes manufactured for biodosimetry testing. A user tracking system is also implemented and tested. Data is then communicated to a cyber-secure cloud server for archiving and app updates. The new APP interfaces to a secure, SOC2 Certified, HIPAA compliant cloud when the data will be communicated, thus providing user access to images and results via a web portal, and archiving, accessible only with appropriate roles and privileges. A user training manual is documented as well as a brief video tutorial made available for download, as applicable.

[0178] Example 2: SAMURAI Kit for point-of-care biodosimetry screening. Further to Example 1, the POC device is further characterized and tested, as additionally described in FIGs. 18-22.

[0179] As explained, the POC device incorporates a VFI platform that integrates all components to detect protein and transcripts in blood cells from fingerstick sampling, without the need of power supply or trained users, and able to distinguish exposed from unexposed individuals following an ionizing radiation event. Importantly, the simple design confers an important versatility to the platform that is readily adapted for any future validated biodosimetry or radiation injury proteo-transcriptomics signature. Overall, the SAMURAI can be used beyond radiation dosimetry for the diagnosis, prognostic or monitoring of a large panel of conditions requiring detection of intracellular biomarkers.

[0180] FIG. 18 (see also FIG. 11A and 14) illustrates the main components of a POC device, including a sample preparation module (SPM) and vertical flow immunoassay (VFI) module. Within the SPM is a sample container 10 having a passage 15 configured to receive a fluid sample into the fluid chamber 20 and a sample container material 30 positioned on a bottom surface 11. Sample container piercing insert 40 forms one end of a sample container volume 50. Top vessel 100 (labelled “top container” in FIG. 14), has a waste chamber 110, buffer solution chamber 120 (e.g., various lysis buffers, including a primary buffer solutionAtty Ref. 341049: 61-24 WOchamber 121; lateral buffer solution chamber(s) 122), bottom material 130 (preferably, the bottom material is a bottom film) that piercing insert can pierce. Membrane housing 200 contains membrane housing piercing insert 210, membrane pad 220, and connects to bottom cap 300. Various components may be threadably (14013) connected, such that rotation motion may tighten or loosen the connection, including a threaded connection 140 between an outer surface 101 of top vessel 100 and inner surface 12 of sample container 20. Similarly, threaded connection 13 may be between outer surface 14 of sample container 20 and inner surface 201 of membrane housing. Magnetic clamp 505 may be positioned around at least a portion of outer surface of the membrane housing. Alignment marker 805 may indicate fully sealed or a fluid access configuration arising from piercing of the material. An o-ring 905 may facilitate fluidic sealing. VFI 1305 is within the membrane housing 200. Capture agent 1605 may bind a target within the fluid sample, including Anti-CD45 to capture WBC’s.

[0181] We explore the detection of radiation biomarkers using a paper-based VFI. Using commercial antibodies, we show that a competitive assay format provides a dose-response and a limit-of-detection (LOD) of - 33.5 ng / mL for the detection of the housekeeping protein P2m and that a sandwich format allows the detection of the biodosimetry protein DDB2 with a LOD of 1.9 ng / mL (FIG. 19 top graphs). Interestingly, the detection of these biomarkers was multiplexed and demonstrated no cross-reactivity and that P2m and DDB2 could be detected on the same membrane with their respective LOD (FIG. 19 bottom photographs). Altogether, these data demonstrate the ability of the VFI to detect, in multiplex, proteins and its improved sensitivity over standard paper-based assays.

[0182] Detection of transcripts using paper-based vertical flow immunoassay. Using labeled primers during standard amplification and a multiplex membrane, we have previously showed that the VFI can simultaneously detect two biodosimetry genes, CDKN1 A and DDB2, as well as one housekeeping gene MRPS5 [9], The assay demonstrated its ability to discriminate non-irradiated controls (0 Gy) from irradiated samples (1 + 2 Gy) with an overall sensitivity of 62.5% and specificity of 100%. This gene combination also shows a dose-dependent response for 0, 1, and 2 Gy, similar to data obtained by real-time PCR benchmark. Recently, we have reproduced these results using an isothermal amplification, supporting development of a VFI integrated with sample preparation. Interestingly, we also show that by applying an immuno-based approach for the detection of transcripts, the VFI can simultaneously provide information for both protein and genes on the same membrane.Atty Ref. 341049: 61-24 WOAs a proof-of-concept, we combined detection of P2m and DDB2 proteins (as shown in FIG.19) with CDKN1A, DDB2 and MRPS5, previously amplified by recombinase polymerase amplification (FIG. 20). The assay independently detects each target without cross-reactivity, highlighting the unique feature of the VFI to identify biomarkers of different nature.

[0183] To integrate the sample preparation in POC device, there is a need to minimize handling for each step to better facilitate integration. Therefore, we recently developed a protocol to lyse RBCs using a buffer that also allows binding of remaining leukocytes to anti-CD45 antibody. We first assessed RBC lysis efficiency of two commercial buffers (ACK and EL) and water (H2O) as a hypotonic solution. Results showed that all buffers lysed RBCs after 10 min incubation, with water being also able to lyse RBCs after 10 s only (FIG. 21 A).We then selected these 4 efficient conditions for RBC lysis to assess if leukocytes could bind anti-CD45 antibodies during RBC lysis. Results showed that leukocytes incubated for 10 min in EL buffer bound to anti-CD45 antibody while water and ACK prevented the interaction (FIG. 21B). However, water, supplemented with 10% 10X PBS after 10 s to neutralize RBC lysis and reestablish isotonic condition, proved to be the best solution to promote binding.

[0184] We have demonstrated that the VFI is more sensitive than LFI and ELISA to detect pathogen proteins [7], can be miniaturized to improve its sensitivity

[0039] , and can detect multiple targets [8], including gene transcripts by immunoassay [9], However, the operation of this current VFI relies mainly on external force (i.e., syringe pump) to help the sample flow through layers of stacked pads. The operation of the SAMURAI device is based on a capillary-driven force, thus allowing usage without the need of powered equipment. We developed a paper-based multiplexed microgravity-adapted Vertical Flow Immunoassay (0g-VFI) to detect plasma Immunoglobulin M (IgM) and C-reactive protein (CRP) during the allcivilian SpaceX Inspiration4 mission

[0010] , The Og-VFI is a simplified VFI that consists of a stacked multilayer of pads and membranes assembled in 3D-printed plastic caps and capsules (FIG. 11 A). Plasma is isolated from fingerstick-collected WB using a plasma separator cartridge and directly dispensed on the sample pad. The capsule containing an assay buffer-loaded pad (wet pad) is used to make contact with the absorbing pad and trigger fluid transfer through the pads and membrane by capillarity. All assay buffers and reagents are dried or sealed in caps, reducing risk of exposure to hazardous chemicals. Overall, the assay takes up to 20 min due to its simple workflow. Assessment of cross-reactivity and specificity showed no significant non-specific binding, with a minimal background sometimes visible for IgMAtty Ref. 341049: 61-24 WO(FIG. 22 - panel “a)”). The limit of detection for CRP and IgM was 0.01 and 0.7 pg / mL, respectively (FIG. 22 - panel “b)”). However, although the intra- and inter-assay CV were < 20% (FIG. 22 - panel “c)”), the large distribution of data was the result of a low spatial distribution homogeneity across the membrane (FIG. 22 - panels “d)-e)”), highlighting the need of optimizing flow rate and distribution. In-flight, the Og-VFI also demonstrated its robustness of operation in a microgravity environment, and the simplicity of its user interface allowed its use by untrained, non- scientists. Overall, these data highlights the potential of capillary-driven VFI as POC device, whose multiplexing and simplicity confer great potential for application such as emergency biodosimetry devices. Based on this, Og-VFI is integrated with the SPM as the VFI module and optimize its overall design to provide a stable and functional detection module to the SAMURAI kit.

[0185] Example 3: SAMURAI Exemplary Devices. Various schematics of the POC device are illustrated. For example, FIGs 23A-23F summarize SAMURAI connection diagrams at various process points, spanning from starting point with starting reagents / buffers to liquid sample flowing into the VFI. Note, for reliability of use and cost-effectiveness, the “valves” illustrated may be functionally replaced with pierceable membranes and piercing elements to facilitate flow of sample fluid, buffers, and the like between various functional elements. Similarly, the syringes may be replaced with fluid compartments having membranes that may be reliably ruptured to ensure flow of fluid out of a compartment to a desired region or component. FIG. 24 are different views of various fluids being provided to a POC device, including via syringe. FIG. 25 illustrates another embodiment.

[0186] Example 4: Surveillance & Protection for Emergency Early Detection using Autonomous Handheld Environmental Analytical Device (SPEED-AHEAD) kit.

[0187] A handheld nimble system with safe and limited user contact for multiple biological agents, including known Biological Warfare Agents, capable of rapidly identifying hazards in various environmental or clinical samples is crucial in assisting the warfighter during military operations to make informed decisions. The functional specifications of such a prototype mandate for the development of a self-operated handheld device that can rapidly, and autonomously monitor and alert the user to unsafe environmental exposure, without further burdening the warfighter’s payload or interfering with the primary mission. Sensitive nucleic acid-based detection utilizing benchtop systems are readily available in laboratory settings, but there is a need for rapid, multiplex, remote threats detection in environmental samplesAtty Ref. 341049: 61-24 WO(e.g., wastewater, surfaces, livestock) and / or in biological fluids (e.g., blood, urine) in the field. One of the major challenges in nucleic acid (NA) assays is the requirement for sophisticated instrumentation and sample processing that can be time consuming, possibly causing sample degradation, and often interfacing with slow and power- consuming detectors. To address these concerns, provided herein is the safe self- operated and powerless SPEED-AHEAD. This platform integrates several novel engineering approaches and assay technologies required to perform sample collection and preparation, bioassay, detection, automated data analysis and reporting, offering to the user a versatile tool to quickly inform on the presence or absence of a multitude of biological threats in under 30 minutes directly into the operational mission theater. The bioassay chemistry integrated in this platform to detect nucleic acid uses DNA:RNA hybrid detection method that does not require amplification and is thus simplified and easier to integrate into a point-of-care (POC) device. The flexibility of this POC device extends beyond radiological exposure assays with a range of multiplexing agents that simultaneously can enhance performance. This makes this POC device readily adaptable for detection of other emerging threats, or monitoring clinical biomarkers for disease management, thus broadening its appeal to encompass a range of applications.

[0188] Provided is a POC device that is light-weight, powerless, and functions as a self-sustainable kit that is able to remotely detect / identify Chemical Biological Agents (CBA) into environmental samples, such as water, or in clinical samples, such as blood, urine or saliva under remote conditions. The relevance of this device to the Warfighter (or other remote user) is the increased ability to quickly identify and take actions towards potentially dangerous CBA agents under field conditions, allowing for near real- time decision making that can drastically improve the Warfighter’s performance in the field or health, safety and treatment of a remote user overall. The SPEED-AHEAD kit is intended to be portable (hand-held) to minimize the burden on the warfighter while providing the ability to process a sample without the need of an electrically powered instrument and quickly identify a multitude of threats, alerting a warfighter to the risk of exposure in less than 30 minutes.

[0189] A functional SPEED-AHEAD kit provides a handheld device capable of multiplexed detection of a wide variety of single-stranded RNA viruses that include filoviruses (e.g., Ebola, Marburg viruses) and alphaviruses (e.g., Eastern, Western and Venezuelan equine encephalitis virus). The SPEED-AHEAD kit is a self-contained unit thatAtty Ref. 341049: 61-24 WOdoes not require rechargeable or commercial battery with run time of about 30 minutes and is equipped with cybersecure image analysis algorithm configurated into a smartphone App (e.g., iOS, Android, etc.) capable of identifying a biological threat in a complex background and in a variety of samples with a low false alarm rate. This product development leverages the Vertical Flow Immunoassay (VFI) detection, including of Tier 1 bacterial pathogens in human blood samples. Then, a simplified powerless VFI device (OMTEST) that consists of a stacked multilayer of pads and membranes assembled in plastic caps and capsules was developed as a POC device for space missions with extreme remote environmental conditions and successfully tested for inflammation and immune blood markers during the all-civilian crew flight Inspiration 4 for a 3-day mission onboard of Space X Dragon spacecraft in orbit.

[0190] SPEED-AHEAD integrated device design and rapid prototyping is by 3D printing and soft injection molding; fluidic and biological testing of the SPM module, verification of environmental sample collection device for input into the SPM, development and characterization of the SPM heating system; VFI module optimization for the SPEED-AHEAD detection, membrane multiplex printing; integration of the benchtop bioassay and reagents formulation into the SPEED-AHEAD kit; environmental samples usability and initial performance review to assess the capacity of the SPEED-AHEAD kit to differentiate multiple single-stranded RNA viruses; establish specifications of the software App; evaluation of reagent stability and storage condition and preparation for mass quality manufacturing and Design History File and Quality Control documentation for commercialization. System requirements is summarized in Table 4.

[0191] The SPEED-AHEAD kit is an integrated POC device designed to perform in-field detection of exposed vs. unexposed environmental or clinical samples to single-stranded RNA viruses within 30 minutes using environmental swabs and collection (FIG. 26). The SPEED-AHEAD kit includes a power-free heated POC SPM in which the swab is inserted after collection to perform viral lysis, NA release and hybridization with DNA probes. The processed NAs are then transferred to a VFI module to simultaneously detect multiplex viral genomes. This workflow does not require

[0192] The SPEED-AHEAD kit is an integrated POC device designed to perform in-field detection of exposed vs. unexposed environmental or clinical samples to single-stranded RNA viruses within 30 minutes using environmental swabs and collection (Fig. 2). The SPEED-AHEAD kit includes a power-free heated POC SPM in which the swab is inserted afterAtty Ref. 341049: 61-24 WOcollection to perform viral lysis, NA release and hybridization with DNA probes. The processed NAs are then transferred to a VFI module to simultaneously detect multiplex viral genomes. This workflow does not require electrical power, thus minimizing platform size and cost, making the SPEED-AHEAD kit perfectly suitable for POC usage. The simplicity and convenient user interface of the SPEED-AHEAD kit allow the assay to be performed by untrained military personnel or by self-testing in the field. Membrane data are captured and analyzed by a smartphone-based App and uploaded to a secure cloud to provide results in 30 min from sample collection. Note a direct naked eye visualization of the membrane can also be performed if access to a smartphone would be compromised or unavailable.

[0193] The SPEED-AHEAD kit is targeted for use across environmental conditions. This device is developed with the broadest flexibility in mind to be upgraded in under 2 months of being presented with a new threat target. Therefore, provided is a multiplex NA assay to detect single-stranded RNA viruses which can be quickly adapted for the detection of emerging biological threats, including single-stranded viruses, more prone to mutate and that often constitute the main reservoir of new and rapid-spreading infections. Preferably, sample is provided to the device via swab loading.

[0194] The SPEED-AHEAD platform lays down on several technological advances that we have developed. A paper-based VFI device identifies biological agents of potential threats to overcome the limitations of the standard methods such as microbiological cultivation. This approach allowed us to demonstrate that the VFI, the core technology of the SPEED-AHEAD kit, shows great potential as a POC tool for the detection of Burkholderia pseudomallei capsular polysaccharide with a sensitivity of 0.02 ng / ml [Cheng et al. Taianta. 2019], We miniaturized the device even more and created an automated ancillary platform to provide a portable VFI for military missions to detect six Tier 1 biothreats in multiplex [Devadhasan et al., Analytical Chemistry, 2021 and Devadhasan, et al., Biosensors & Bioelectronics, 2023], Finally, with the goal of fulfilling the need of a true handheld device, we modify the VFI design to remove the ancillary pump system and provide a VFI device that relies on capillary force and, therefore, does not require any power supply, making the instant POC device smaller, lighter, cost-effective, and more adapted for handheld applications. This device has been tested during the Inspiration4 mission (SpaceX) where the VFI demonstrated its ability to detect plasma protein and function in extreme remote environment (i.e. microgravity, space vehicle operations). For this project, the simplified “powerless” version of the VFI areAtty Ref. 341049: 61-24 WOadapted to detect the genome of viral agents (single-stranded RNA). To facilitate the integration of nucleic acid assay in our VFI platform, we will develop an amplification-free approach based on the hybridization of single-stranded DNA (i.e., DNA probes) with RNA. The detection is possible through the binding of a gold nanoparticle conjugated-S9.6 monoclonal antibody known for its high affinity and selectivity to DNA:RNA hybrid molecules (FIG. 9). The binding of DNA:RNA hybrids by the S9.6 monoclonal antibody does not have sequence specificity, and its molar ratio to DNA:RNA hybrid was documented to be 11-13 under certain conditions, suggesting that a hybrid can bind to more than a dozen antibodies, leading to a significant signal amplification [Poljak et al., Expert Rev Anti Infect Ther. 2010], This approach has been recently implemented for the detection of SARS-CoV-2, a single-stranded RNA virus [Wang D. et al., Nat Biomed Eng. 2020], and has even been approved by FDA for the simultaneous detection of 13 high-risk HPV subtypes [Ding S., et al., Sci Rep. 2015],

[0195] SPEED-AHEAD platform represents a significant advance in the evolution of handheld compact NA-based CBA detection. The SPEED-AHEAD system is an innovative integration of several technologies, combining unique sample preparation method and detection technologies including, amplification-free NA bioassay, multiplex VFI endpoint, Smartphone Software App for data analysis and communication into a rapid, handheld, automated multiplex biothreat analysis platform, integrated into an easy-to-use field device without the need for electrical power. No such integrated system is available. This product platform is readily agile, scalable, and mass manufacturable.

[0196] . The SPEED-AHEAD technology involves an innovative integration of several proprietary technologies. See, for example, WO 2023 / 018982 (“Safe self-testing of multiplex biomarkers in biofluids”); US Pat. No. 11,860,160 (“Vertical flow molecular assay apparatus”); US Pub. No. 20240277322 (“Biofluid self-collection and processing device”).

[0197] Of particular relevance, the devices, kits and methods provided herein have a range of applications, including for testing any of a range of samples, including environmental or biosamples. Depending on the marker of interest, suitable reagents, capture agents and tests are selected depending on the sample of interest. For biological samples, including whole blood, specific optimized panels of proteins and NA signatures in the biodosimetry panels, tailored to whole blood samples and intracellular biomarkers are provided. The devices provided herein are, of course, suitable for use with other types of samples and applications.Atty Ref. 341049: 61-24 WO

[0198] The devices are configured to ensure that fluid is appropriately collected, processed and detected. Accordingly, there is controlled and directed fluid flow between the various components when desired by the user. The devices are versatile in that the components are functionally integrated and provide continuous processing of the sample, ranging from sample preparation to detection. The final detection can be by delivery of fluid to a sensor that is provided in the form of a membrane that analyzes / interrogates the sample to thereby characterize the sample. This membrane can be a VFI membrane having an array of capture agents (also referred herein as probes) to capture a marker, such as to provide characterization of a presence or absence of a specific protein or nucleic acid, thereby detecting a marker in the sample. The “sensor membrane” can be static or can be reversibly activated via chemistry, such as by adding a detachment reagent (e.g. enzyme) to expose the probes to a next cycle of detection allowing a more continuous analysis. On the membrane or the device container, some sensors can be added for physical measurements such as pH, temperature and / or electrical signals (e.g. TEER).STATEMENTS REGARDING INCORPORATION BY REFERENCE AND VARIATIONS

[0199] All references throughout this application, for example patent documents including issued or granted patents or equivalents; patent application publications; and non-patent literature documents or other source material; are hereby incorporated by reference herein in their entireties, as though individually incorporated by reference, to the extent each reference is at least partially not inconsistent with the disclosure in this application (for example, a reference that is partially inconsistent is incorporated by reference except for the partially inconsistent portion of the reference).

[0200] The terms and expressions which have been employed herein are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments, exemplary embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims. The specific embodimentsAtty Ref. 341049: 61-24 WOprovided herein are examples of useful embodiments of the present invention and it will be apparent to one skilled in the art that the present invention may be carried out using a large number of variations of the devices, device components, methods, or steps set forth in the present description. As will be obvious to one of skill in the art, methods and devices useful for the present methods can include a large number of optional composition and processing elements and steps.

[0201] As used herein and in the appended claims, the singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to "a cell" includes a plurality of such cells and equivalents thereof known to those skilled in the art. As well, the terms "a" (or "an"), "one or more" and "at least one" can be used interchangeably herein. It is also to be noted that the terms "comprising", "including", and "having" can be used interchangeably. The expression “of any of claims XX- YY” (wherein XX and YY refer to claim numbers) is intended to provide a multiple dependent claim in the alternative form, and in some embodiments is interchangeable with the expression “as in any one of claims XX- YY.”

[0202] When a group of substituents is disclosed herein, it is understood that all individual members of that group and all subgroups, are disclosed separately. When a Markush group or other grouping is used herein, all individual members of the group and all combinations and subcombinations possible of the group are intended to be individually included in the disclosure.

[0203] Whenever a range is given in the specification, for example, a temperature range, a time range, or a composition or concentration range, all intermediate ranges and subranges, as well as all individual values included in the ranges given are intended to be included in the disclosure. It will be understood that any subranges or individual values in a range or subrange that are included in the description herein can be excluded from the claims herein.

[0204] All patents and publications mentioned in the specification are indicative of the levels of skill of those skilled in the art to which the invention pertains. References cited herein are incorporated by reference herein in their entirety to indicate the state of the art as of their publication or filing date and it is intended that this information can be employed herein, if needed, to exclude specific embodiments that are in the prior art. For example, when compositions of matter are claimed, compounds known and available in the art prior toAtty Ref. 341049: 61-24 WOApplicant's invention, including compounds for which an enabling disclosure is provided in the references cited herein, are not intended to be included in the composition of matter claims herein.

[0205] As used herein, “comprising” is synonymous with "including," "containing," or "characterized by," and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. As used herein, "consisting of excludes any element, step, or ingredient not specified in the claim element. As used herein, "consisting essentially of does not exclude materials or steps that do not materially affect the basic and novel characteristics of the claim. In each instance herein any of the terms "comprising", "consisting essentially of and "consisting of may be replaced with either of the other two terms. The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein.

[0206] One of ordinary skill in the art will appreciate that starting materials, biological materials, reagents, synthetic methods, purification methods, analytical methods, assay methods, and biological methods other than those specifically exemplified can be employed in the practice of the invention without resort to undue experimentation. All art-known functional equivalents of any such materials and methods are intended to be included in this invention. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims.

[0207] In general, the terms and phrases used herein have their art-recognized meaning, which can be found by reference to standard texts, journal references and contexts known to those skilled in the art.Atty Ref. 341049: 61-24 WOSTATEMENTS REGARDING INCORPORATION BY REFERENCE AND VARIATIONS

[0208] All references throughout this application, for example patent documents including issued or granted patents or equivalents; patent application publications; and non-patent literature documents or other source material; are hereby incorporated by reference herein in their entireties, as though individually incorporated by reference, to the extent each reference is at least partially not inconsistent with the disclosure in this application (for example, a reference that is partially inconsistent is incorporated by reference except for the partially inconsistent portion of the reference).

[0209] The terms and expressions which have been employed herein are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments, exemplary embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims. The specific embodiments provided herein are examples of useful embodiments of the present invention and it will be apparent to one skilled in the art that the present invention may be carried out using a large number of variations of the devices, device components, methods, or steps set forth in the present description. As will be obvious to one of skill in the art, methods and devices useful for the present methods can include a large number of optional composition and processing elements and steps.

[0210] As used herein and in the appended claims, the singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to "a cell" includes a plurality of such cells and equivalents thereof known to those skilled in the art. As well, the terms "a" (or "an"), "one or more" and "at least one" can be used interchangeably herein. It is also to be noted that the terms "comprising", "including", and "having" can be used interchangeably. The expression “of any of claims XX- YY” (wherein XX and YY refer to claim numbers) is intended to provide a multiple dependentAtty Ref. 341049: 61-24 WOclaim in the alternative form, and in some embodiments is interchangeable with the expression “as in any one of claims XX- YY ”

[0211] When a group of substituents is disclosed herein, it is understood that all individual members of that group and all subgroups, are disclosed separately. When a Markush group or other grouping is used herein, all individual members of the group and all combinations and subcombinations possible of the group are intended to be individually included in the disclosure.

[0212] Whenever a range is given in the specification, for example, a temperature range, a time range, or a composition or concentration range, all intermediate ranges and subranges, as well as all individual values included in the ranges given are intended to be included in the disclosure. It will be understood that any subranges or individual values in a range or subrange that are included in the description herein can be excluded from the claims herein.

[0213] All patents and publications mentioned in the specification are indicative of the levels of skill of those skilled in the art to which the invention pertains. References cited herein are incorporated by reference herein in their entirety to indicate the state of the art as of their publication or filing date and it is intended that this information can be employed herein, if needed, to exclude specific embodiments that are in the prior art. For example, when compositions of matter are claimed, it should be understood that compounds known and available in the art prior to Applicant's invention, including compounds for which an enabling disclosure is provided in the references cited herein, are not intended to be included in the composition of matter claims herein.

[0214] As used herein, “comprising” is synonymous with "including," "containing," or "characterized by," and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. As used herein, "consisting of excludes any element, step, or ingredient not specified in the claim element. As used herein, "consisting essentially of does not exclude materials or steps that do not materially affect the basic and novel characteristics of the claim. In each instance herein any of the terms "comprising", "consisting essentially of and "consisting of may be replaced with either of the other two terms. The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein.Atty Ref. 341049: 61-24 WO

[0215] One of ordinary skill in the art will appreciate that starting materials, biological materials, reagents, synthetic methods, purification methods, analytical methods, assay methods, and biological methods other than those specifically exemplified can be employed in the practice of the invention without resort to undue experimentation. All art-known functional equivalents of any such materials and methods are intended to be included in this invention. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims.

[0216] In general, the terms and phrases used herein have their art-recognized meaning, which can be found by reference to standard texts, journal references and contexts known to those skilled in the art.Atty Ref. 341049: 61-24 WOTABLESTable 1: Indications and UsageDESCRIPTION Protein and Transcript assay; Input about 100 uL whole blood Clinical Pharmacology No Pharmacology is applicableIndications and Usage Exposure to radiation from INDContraindications Not applicableWarnings Normal blood handling protocols and procedures Precautions Normal blood handling protocols and proceduresAdverse Reactions None known at this time (TBD)Drug Abuse and Dependence Not applicableOverdosage Not applicableDosage and Administration Not applicableHow Supplied Whole blood is collected from a fingerprick and drawn into a capillary container / tube which is input into the Biodosimeter deviceAnimal Pharmacology and / or Animal Need for large animal studies - model (e.g. porcine or NHP) yet Toxicology to be determinedClinical Studies Clinical studies - yet to be determined.Table 2: Performance Specifications and FeaturesModule SAMURAI Features Performance SpecificationBlood Collection Auto-loading of blood collection >100 ul blood samples can be loaded per device Interface to Device Capillary tube using a blood lancet such as BD Microtainer (510k registration# 2243072) and Minivette™ collection device from Sarstedt (51 OK registration #K031359).Hybrid Assay Paper-based detection Radiation exposed vs. unexposedAmplification-free transcript Sensitivity will be determined for AUROC > 0.8 detectionProtein sandwich immunoassaySAMURAI Designed and manufactured for Alpha Device: 5” (L) x 1.5” (OD); carton kit 12” x Device injection molding by medical device 12” x 4” (incl. parts and reagents)manufacturers (TBD)Beta System: kit to be optimized for pallet Totally Automated System; Self- stockpiling in warehouseassisted POCWeight = <3 lbs (estimated)Atty Ref. 341049: 61-24 WOCompatible with iOS smartphoneimager runtime = approx. 30 minSelf-contained, in device storage of Water, dust, shock resistantreagents Environmental SensitivitiesEase of Use: POC Humidity: 20% to 75% RH Temperature: 20-70° CMeets CDRH and / or CLIA Device sensitivity to radiation: minimal requirementsShelf-Life disposables; > 3 years Useful Life; > 3 yearsNo power requirements.Smartphone CCD detection 48-bit TIFF formatImageriOS compatibleResult Secure data communication protocols Can be exported via tiff, gif or Apple iPhone Reporting supported formatNetwork based enabling platformPatient ID’s and analytical results can beelectronically linked.Table 3. A UROC values from six individual biomarkers to discriminate radiation dose < 2 Gy and>2 Gy (from

[0015] ). _BIOMARKE R DAY ACTN1 BAX FDXR p53 DDB2 TSPYL2 0.996 0.988 0.741 0.873 0.973 0.977 Day 2 (p <0.001) (p <0.001) (p <0.001) (p <0.001) (p <0.001) (p <0.001) 0.984 0.977 0.765 0.820 0.744 0.992 Day 4 (p <0.001) (p <0.001) (p <0.001) (p <0.001) (p <0.001) (p <0.001) 0.979 0.833 0.833 0.602 0.863 0.884Day 8 (p <0.001) (p <0.001) (p <0.001) (p <0.001) (p <0.001) (p <0.001)Table 4. System Critical Requirements (Example 4 - SPEED- AHEAD):Cycle Time The instrument shall detect multiplex nucleic acids-based markers of Biological Warfare Agents including single -stranded RNA viruses in less than 30 min Detection The SPEED-AHEAD device / kit shall automate the running of the entire workflow from sample collection, control all required sample preparation functions, perform NA detection analysis with up to 95% accuracy, data collection and data analysis without any direct user contact with the sample, nor using any electrically powered device.Quality Standards The SPEED-AHEAD device shall be compatible with UL and MIL-STD 810 or other standardsField Portable The SPEED-AHEAD shall be a handheld detector / deviceNetworking The device shall have networking capabilities compatible with militarycommunications systems and protocols, as well as be cybersecure.Atty Ref. 341049: 61-24 WOData Processing The device shall be capable of performing all data processing requirements, display an alarm signal and deliver a classification report of the level and nature of biothreats detected in about 30 min.Power The device shall not require any electrical power to operate (powerless) Installation The device shall be capable of being transported to new locations without any set-up requirements aside from connecting to an electronic appliance like a smartphone (or other equivalent handheld reader if applicable)Device Tracking The device shall be equipped with suitable sample identification and / or trackinghardware and database (if applicable)Table of References (including from Example 2):1. Ramesh AC, Kumar S. Triage, monitoring, and treatment of mass casualty events involving chemical, biological, radiological, or nuclear agents. J Pharm Bioallied Sci. 2010;2: 239-247. doi: 10.4103 / 0975-7406.685062. Abend M, Amundson SA, Badie C, Brzoska K, Kriehuber R, Lacombe J, et al.RENEB Inter-Laboratory Comparison 2021: The Gene Expression Assay. Radiation Research. 2023 [cited 11 May 2023], doi:10.1667 / RADE-22-00206.13. Lacombe J, Sima C, Amundson SA, Zenhausern F. Candidate gene biodosimetry markers of exposure to external ionizing radiation in human blood: A systematic review.PLOS ONE. 2018; 13 : e0198851. doi:10.1371 / journal.pone.01988514. Paul S, Amundson SA. Development of gene expression signatures for practical radiation biodosimetry. Int J Radiat Oncol Biol Phys. 2008;71: 1236-1244. doi:10.1016 / j.ijrobp.2008.03.0435. Wang Q, Lee Y, Shuryak I, Pujol Canadell M, Taveras M, Perrier JR, et al.Development of the FAST-DOSE assay system for high-throughput biodosimetry and radiation triage. Sci Rep. 2020;10: 12716. doi: 10.1038 / s41598-020-69460-76. Lee Y, Pujol Canadell M, Shuryak I, Perrier JR, Taveras M, Patel P, et al. Candidate protein markers for radiation biodosimetry in the hematopoietically humanized mouse model. Sci Rep. 2018;8: 13557. doi : 10.1038 / s41598-018-31740-87. Chen P, Gates-Hollingsworth M, Pandit S, Park A, Montgomery D, AuCoin D, et al. Paper-based Vertical Flow Immunoassay (VFI) for detection of bio-threat pathogens. Taianta.2019;191: 81-88. doi:10.1016 / j.talanta.2018.08.0438. Devadhasan JP, Summers AJ, Gu J, Smith S, Thomas B, Fattahi A, et al. Point-of-care vertical flow immunoassay system for ultra-sensitive multiplex biothreat-agent detectionAtty Ref. 341049: 61-24 WOin biological fluids. Biosensors and Bioelectronics. 2023;219: 114796.doi: 10.1016 / j. bios.2022.1147969. Lacombe J, Summers AJ, Khanishayan A, Khorsandian Y, Hacey I, Blackson W, et al. Paper-Based Vertical Flow Immunoassay for the Point-of-Care Multiplex Detection of Radiation Dosimetry Genes. Cytogenet Genome Res. 2023;163: 178-186.doi: 10.1159 / 00053170210. Jones CW, Overbey EG, Lacombe J, Ecker AJ, Meydan C, Ryon K, et al. Molecular and physiologic changes in the SpaceX Inspiration4 civilian crew. Nature. In Press.11. Satyamitra MM, DiCarlo AL, Hollingsworth BA, Winters TA, Taliaferro LP.Development of Biomarkers for Radiation Biodosimetry and Medical Countermeasures Research: Current Status, Utility, and Regulatory Pathways. RadiatRes. 2022;197: 514-532. doi :10.1667 / RADE-21-00157.112. Hladik D, Bucher M, Endesfelder D, Oestreicher U. The Potential of Omics in Biological Dosimetry. Radiation. 2022;2: 78-90. doi:10.3390 / radiation201000613. Azimzadeh O, Moertl S, Ramadan R, Baselet B, Laiakis EC, Sebastian S, et al.Application of radiation omics in the development of adverse outcome pathway networks: an example of radiation-induced cardiovascular disease. Int J Radiat Biol. 2022;98: 1722-1751. doi: 10.1080 / 09553002.2022.211032514. Aryankalayil MJ, Bylicky MA, Chopra S, Dalo J, Scott K, Ueda Y, et al. Biomarkers for Biodosimetry and Their Role in Predicting Radiation Injury. Cytogenet Genome Res. 2024;163: 103-109. doi: 10.1159 / 00053144415. Association (ATA) LSC of the AT. Point-of-Care Thyroid Diagnostics and Thyroid Disease Management. 2019 [cited 8 May 2024], Available: https: / / policycommons.net / artifacts / 1687324 / point-of-care-thyroid-diagnostics-and-thyroid-disease-management / 2418969 / 16. Shafiee H, Wang S, Inci F, Toy M, Henrich TJ, Kuritzkes DR, et al. Emerging technologies for point-of-care management of HIV infection. Annu Rev Med. 2015;66: 387-405. doi : 10.1146 / annurev-med-092112-14301717. Haleyur Giri Setty MK, Hewlett IK. Point of Care Technologies for HIV. AIDS Research and Treatment. 2014;2014: e497046. doi: 10.1155 / 2014 / 49704618. Mauk M, Song J, H. Bau H, Gross R, D. Bushman F, G. Collman R, et al.Miniaturized devices for point of care molecular detection of HIV. Lab on a Chip. 2017;17: 382-394. doi:10.1039 / C6LC01239FAtty Ref. 341049: 61-24 WO19. Song Q, Sun X, Dai Z, Gao Y, Gong X, Zhou B, et al. Point-of-care testing detection methods for COVID-19. Lab Chip. 2021;21: 1634-1660. doi:10.1039 / D0LC01156H20. Narayanamurthy V, E. Jeroish Z, S. Bhuvaneshwari K, Samsuri F. Hepatitis C virus (HCV) diagnosis via microfluidics. Analytical Methods. 2021; 13: 740-763.doi : 10.1039 / DO AY02045 A21. Jia Y, Sun H, Tian J, Song Q, Zhang W. Paper-Based Point-of-Care Testing of SARS-CoV-2. Frontiers in Bioengineering and Biotechnology. 2021;9. Available: https: / / www.firontiersin.org / articles / 10.3389 / fbioe.2021.77330422. Chang M, Steinmetzer K, Raugi DN, Smith RA, Ba S, Sall F, et al. Detection and differentiation of HIV-2 using the point-of-care Alere q HIV-1 / 2 Detect nucleic acid test. Journal of Clinical Virology. 2017;97: 22-25. doi: 10.1016 / j.jcv.2017.10.01323. Ceffa S, Luhanga R, Andreotti M, Brambilla D, Erba F, Jere H, et al. Comparison of the Cepheid GeneXpert and Abbott M2000 HIV-1 real time molecular assays for monitoring HIV-1 viral load and detecting HIV-1 infection. Journal of Virological Methods. 2016;229: 35-39. doi:10.1016 / j.jviromet.2015.12.00724. Zhu X, Wang X, Han L, Chen T, Wang L, Li H, et al. Multiplex reverse transcription loop-mediated isothermal amplification combined with nanoparticle-based lateral flow biosensor for the diagnosis of COVID-19. Biosensors and Bioelectronics. 2020; 166: 112437. doi: 10.1016 / j. bios.2020.11243725. Garneret P, Coz E, Martin E, Manuguerra J-C, Brient-Litzler E, Enouf V, et al.Performing point-of-care molecular testing for SARS-CoV-2 with RNA extraction and isothermal amplification. PLOS ONE. 2021;16: e0243712.doi: 10.1371 / journal. pone.024371226. Yu S, Nimse SB, Kim J, Song K-S, Kim T. Development of a Lateral Flow Strip Membrane Assay for Rapid and Sensitive Detection of the SARS-CoV-2. Anal Chem.2020;92: 14139-14144. doi:10.1021 / acs.analchem.0c0320227. Xia S, Chen X. Single-copy sensitive, field-deployable, and simultaneous dual-gene detection of SARS-CoV-2 RNA via modified RT-RPA. Cell Discov. 2020;6: 1-4.doi : 10.1038 / s41421 -020-0175-x28. Qian J, Boswell SA, Chidley C, Lu Z, Pettit ME, Gaudio BL, et al. An enhanced isothermal amplification assay for viral detection. Nat Commun. 2020;ll: 5920.doi : 10.1038 / s41467-020- 19258-y29. Ritchie AV, Ushiro-Lumb I, Edemaga D, Joshi HA, De Ruiter A, Szumilin E, et al. SAMBA HIV Semiquantitative Test, a New Point-of-Care Viral-Load-Monitoring Assay forAtty Ref. 341049: 61-24 WOResource-Limited Settings. Journal of Clinical Microbiology. 2014;52: 3377-3383. doi: 10.1128 / JCM.00593-1430. Goel N, Ritchie AV, Mtapuri-Zinyowera S, Zeh C, Stepchenkova T, Lehga J, et al. Performance of the SAMBA I and II HIV-1 Semi-Q Tests for viral load monitoring at the point-of-care. Journal of Virological Methods. 2017;244: 39-45. doi:10.1016 / j.jviromet.2017.03.00131. Ondiek J, Namukaya Z, Mtapuri-Zinyowera S, Balkan S, Elbireer A, Ushiro Lumb I, et al. Multicountry Validation of SAMBA - A Novel Molecular Point-of-Care Test for HIV-1 Detection in Resource-Limited Setting. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2017;76: e52. doi :10.1097 / QAI.000000000000147632. Lee HH, Dineva MA, Chua YL, Ritchie AV, Ushiro-Lumb I, Wisniewski CA. Simple Amplification-Based Assay: A Nucleic Acid-Based Point-of-Care Platform for HIV-1 Testing. The Journal of Infectious Diseases. 2010;20L S65-S72.33. Park J, Han DH, Park J-K. Towards practical sample preparation in point-of-care testing: user-friendly microfluidic devices. Lab Chip. 2020;20: 1191-1203.doi : 10.1039 / D0LC00047G34. Paul R, Ostermann E, Wei Q. Advances in point-of-care nucleic acid extraction technologies for rapid diagnosis of human and plant diseases. Biosensors and Bioelectronics.2020;169: 112592. doi: 10.1016 / j.bios.2020.11259235. Wang J, Yiu B, Obermeyer J, Filipe CDM, Brennan JD, Pelton R. Effects of Temperature and Relative Humidity on the Stability of Paper-Immobilized Antibodies.Biomacromolecules. 2012; 13: 559-564. doi: 10.102 l / bm201740536. Shuryak I, Nemzow L, Bacon BA, Taveras M, Wu X, Deoli N, et al. Machine learning approach for quantitative biodosimetry of partial-body or total-body radiation exposures by combining radiation-responsive biomarkers. Sci Rep. 2023; 13: 949.doi : 10.1038 / s41598-023 -28130-037. Kursa MB. Robustness of Random Forest-based gene selection methods. BMC Bioinformatics. 2014;15: 8. doi: 10.1186 / 1471-2105-15-838. Williams BB, Flood AB, Demidenko E, Swartz HM. ROC Analysis for Evaluation of Radiation Biodosimetry Technologies. Radiat Prot Dosimetry. 2016;172: 145-151. doi:10.1093 / rpd / ncwl6839. Devadhasan JP, Gu J, Chen P, Smith S, Thomas B, Gates-Hollingsworth M, et al. Critical Comparison between Large and Mini Vertical Flow Immunoassay Platforms forAtty Ref. 341049: 61-24 WOYersinia Pestis Detection. Anal Chem. 2021;93: 9337-9344. doi:10.1021 / acs.analchem.0c0527840. Lacombe J, Zenhausern F, Cosson P. AI334, AQ806, AR222, AR249, AS274, AS708, RB572, RB574 and RB596 antibodies recognize SARS-CoV-2 viral particles by dot blot. Antibody Reports. 2020;3: e273-e273. doi:10.24450 / joumals / abrep.2020.e27341. Summers AJ, Devadhasan JP, Gu J, Montgomery DC, Fischer B, Gates-Hollingsworth MA, et al. Optimization of an Antibody Microarray Printing Process Using a Designed Experiment. ACS Omega. 2022;7: 32262-32271. doi:10.1021 / acsomega.2c03595 42. Jazayeri MH, Amani H, Pourfatollah AA, Pazoki-Toroudi H, Sedighimoghaddam B. Various methods of gold nanoparticles (GNPs) conjugation to antibodies. Sensing and BioSensing Research. 2016;9: 17-22. doi:10.1016 / j.sbsr.2016.04.00243. EP05A3: Evaluating Quantitative Measurement Precision. In: Clinical & Laboratory Standards Institute [Internet], [cited 13 May 2024], Available: https: / / clsi.org / standards / products / method-evaluation / documents / ep05 / 44. Zhao Y, Chen F, Li Q, Wang L, Fan C. Isothermal Amplification of Nucleic Acids. Chem Rev. 2015;l 15: 12491-12545. doi:10.1021 / acs.chemrev.5b0042845. Obande GA, Singh KKB. Current and Future Perspectives on Isothermal Nucleic Acid Amplification Technologies for Diagnosing Infections. IDR. 2020;13: 455-483. doi:10.2147 / IDR.S21757146. Wei E, Bou-Nader C, Perry ML, Fattah R, Zhang J, Leppla SH, et al. S9.6 Antibody-Enzyme Conjugates for the Detection of DNA-RNA Hybrids. Bioconjugate Chem. 2023;34: 834-844. doi:10.1021 / acs.bioconjchem.2c0060947. Boguslawski SJ, Smith DE, Michalak MA, Mickelson KE, Yehle CO, Patterson WL, et al. Characterization of monoclonal antibody to DNA.RNA and its application to immunodetection of hybrids. J Immunol Methods. 1986;89: 123-130. doi: 10.1016 / 0022-1759(86)90040-248. Wang D, He S, Wang X, Yan Y, Liu J, Wu S, et al. Rapid lateral flow immunoassay for the fluorescence detection of SARS-CoV-2 RNA. Nat Biomed Eng. 2020;4: 1150-1158. doi : 10.1038 / s41551 -020-00655-z49. Poljak M, Kocjan BJ. Commercially available assays for multiplex detection of alpha human papillomaviruses. Expert Review of Anti-infective Therapy. 2010;8: 1139-1162. doi:10.1586 / eri.10.10450. Ding S, Qian SY, Zhang Y, Wu W, Lu G, Lu Y, et al. Establishment of immunoassay for detecting HPV16 E6 and E7 RNA. Sci Rep. 2015;5: 13686. doi:10.1038 / srep!3686Atty Ref. 341049: 61-24 WO51. Amundson SA, Bittner M, Meltzer P, Trent J, Fornace AJ. Induction of gene expression as a monitor of exposure to ionizing radiation. Radiat Res. 2001;156: 657-661.52. Amundson SA, Do KT, Shahab S, Bittner M, Meltzer P, Trent J, et al. Identification of potential mRNA biomarkers in peripheral blood lymphocytes for human exposure to ionizing radiation. Radiat Res. 2000;154: 342-346.53. Amundson SA, Grace MB, McLeland CB, Epperly MW, Yeager A, Zhan Q, et al. Human in vivo radiation-induced biomarkers: gene expression changes in radiotherapy patients. Cancer Res. 2004;64: 6368-6371. doi:10.1158 / 0008-5472.CAN-04-188354. Ghandhi SA, Shuryak I, Morton SR, Amundson SA, Brenner DJ. New Approaches for Quantitative Reconstruction of Radiation Dose in Human Blood Cells. Sci Rep. 2019;9: 18441. doi : 10.1038 / s41598-019-54967-555. Ghandhi SA, Shuryak I, Ponnaiya B, Wu X, Garty G, Morton SR, et al. Crossplatform validation of a mouse blood gene signature for quantitative reconstruction of radiation dose. Sci Rep. 2022;12: 14124. doi:10.1038 / s41598-022-18558-l56. Paul S, Ghandhi SA, Weber W, Doyle-Eisele M, Melo D, Guilmette R, et al. Gene expression response of mice after a single dose of 137CS as an internal emitter. Radiat Res.2014;182: 380-389. doi: 10.1667 / RR13466.157. Ghandhi SA, Sima C, Weber WM, Melo DR, Rudqvist N, Morton SR, et al. Dose and Dose-Rate Effects in a Mouse Model of Internal Exposure to 137Cs. Part 1: Global Transcriptomic Responses in Blood. Radiat Res. 2020; 196: 478-490. doi: 10.1667 / RADE-20-0004158. Ghandhi SA, Smilenov LB, Elliston CD, Chowdhury M, Amundson SA. Radiation dose-rate effects on gene expression for human biodosimetry. BMC Medical Genomics. 2015;8: 22. doi:10.1186 / sl2920-015-0097-x59. Broustas CG, Xu Y, Harken AD, Chowdhury M, Garty G, Amundson SA. Impact of Neutron Exposure on Global Gene Expression in a Human Peripheral Blood Model. Radiat Res. 2017;187: 433-440. doi:10.1667 / RR0005.160. Broustas CG, Xu Y, Harken AD, Garty G, Amundson SA. Comparison of gene expression response to neutron and x-ray irradiation using mouse blood. BMC Genomics. 2017;18: 2. doi:10.1186 / sl2864-016-3436-l61. Broustas CG, Harken AD, Garty G, Amundson SA. Identification of differentially expressed genes and pathways in mice exposed to mixed field neutron / photon radiation. BMC Genomics. 2018;19: 504. doi:10.1186 / sl2864-018-4884-6Atty Ref. 341049: 61-24 WO62. Mukheijee S, Grilj V, Broustas CG, Ghandhi SA, Harken AD, Garty G, et al. Human Transcriptomic Response to Mixed Neutron-Photon Exposures Relevant to an Improvised Nuclear Device. RadiatRes. 2019;192: 189-199. doi:10.1667 / RR15281.163. Broustas CG, Duval AJ, Amundson SA. Impact of aging on gene expression response to x-ray irradiation using mouse blood. S ci Rep. 2021 ;11: 10177. doi : 10.1038 / s41598-021-89682-764. Suresh Kumar MA, Laiakis EC, Ghandhi SA, Morton SR, Fornace AJ, Amundson SA. Gene Expression in Parpl Deficient Mice Exposed to a Median Lethal Dose of Gamma Rays. RadiatRes. 2018;190: 53-62. doi:10.1667 / RR14990.165. Rudqvist N, Laiakis EC, Ghandhi SA, Kumar S, Knotts JD, Chowdhury M, et al. Global Gene Expression Response in Mouse Models of DNA Repair Deficiency after Gamma Irradiation. RadiatRes. 2018;189: 337-344. doi:10.1667 / RR14862.166. Broustas CG, Mukherjee S, Pannkuk EL, Laiakis EC, Fornace AJ, Amundson SA. Effect of the p38 Mitogen- Activated Protein Kinase Signaling Cascade on Radiation Biodosimetry. RadiatRes. 2022; 198: 18-27. doi: 10.1667 / RADE-21-00240.167. Park JG, Paul S, Briones N, Zeng J, Gillis K, Wallstrom G, et al. Developing Human Radiation Biodosimetry Models: Testing Cross-Species Conversion Approaches Using an Ex Vivo Model System. Radiation Research. 2017;187: 708-721. doi:10.1667 / RR14655.1 68. Nikiforov TT, Rogers YH. The Use of 96-Well Polystyrene Plates for DNA Hybridization-Based Assays: An Evaluation of Different Approaches to Oligonucleotide Immobilization. Analytical Biochemistry. 1995;227: 201-209. doi:10.1006 / abio.1995.1271 69. Poirier Y, Belley MD, Dewhirst MW, Yoshizumic TT, Down JD. Transitioning from Gamma Rays to X Rays for Comparable Biomedical Research Irradiations: Energy Matters. RadiatRes. 2020; 193: 506-511. doi:10.1667 / RADE-20-00039.170. Soni S, Toley BJ. Paper-based nucleic acid sample preparation for point-of-care diagnostics. Sensors and Actuators B: Chemical. 2022;355: 131272. doi:10.1016 / j.snb.202L 13127271. Biedka S, Alkam D, Washam CL, Yablonska S, Storey A, Byrum SD, et al. One-pot method for preparing DNA, RNA, and protein for multiomics analysis. Commun Biol.2024;7: 1-12. doi:10.1038 / s42003-024-05993-l72. Shehadul Islam M, Aryasomayajula A, Selvaganapathy PR. A Review on Macroscale and Microscale Cell Lysis Methods. Micromachines (Basel). 2017;8: 83.doi:10.3390 / mi8030083Atty Ref. 341049: 61-24 WO73. Health C for D and R. eCopy Program for Medical Device Submissions. FDA; 10 Aug 2023 [cited 23 May 2024], Available: https: / / www.fda.gov / regulatory-information / search-fda-guidance-documents / ecopy -program-medical-device-submissions 74. Health C for D and R. Radiation Biodosimetry Medical Countermeasure Devices. FDA; 14 Mar 2019 [cited 23 May 2024], Available: https: / / www.fda.gov / regulatory-information / search-fda-guidance-documents / radiation-biodosimetry-medical-countermeasure-devices75. Joung H-A, Ballard ZS, Ma A, Tseng DK, Teshome H, Burakowski S, et al. Paperbased multiplexed vertical flow assay for point-of-care testing. Lab Chip. 2019; 19: 1027-1034. doi:10.1039 / C9LC00011A76. Joung H-A, Ballard ZS, Wu J, Tseng DK, Teshome H, Zhang L, et al. Point-of-Care Serodiagnostic Test for Early-Stage Lyme Disease Using a Multiplexed Paper-Based Immunoassay and Machine Learning. ACS Nano. 2020; 14: 229-240.doi:10.1021 / acsnano.9b08151

Claims

Atty Ref. 341049: 61-24 WOClaims:

1. A device for detecting a biomarker in a biofluid sample comprising:a sample container comprising:a passage configured to receive the biofluid sample into a sample chamber;a sample container material positioned on a bottom surface of the sample container to fluidically seal the sample container;a sample container piercing insert opposably positioned to the sample container material to form a sample container volume between the sample container piercing insert and the sample container material; a top vessel configured to operably connect to the sample container, wherein the top vessel comprises:a primary buffer solution chamber;a waste chamber;one or more lateral buffer solution chambers;a bottom film that fluidically seals the primary buffer solution chamber and the lateral buffer solution chambers from the sample container, wherein the top vessel is configured for positioning relative to the sample container so that the sample container piercing insert controllably pierces the bottom material for biofluid communication between the top vessel and the sample container;a membrane housing configured to operably connect to the sample container, wherein the sample container is positioned between the top vessel and the membrane housing, the membrane housing containing:a membrane housing piercing insert configured to controllably pierce the sample container material;a membrane pad positioned beneath the piercing insert;a bottom cap connected to a bottom surface of the membrane housing and configured to support the membrane pad;wherein: optionally the sample container material and / or bottom material comprises a controllably pierceable film, sponge or a foam-like material; optionally the piercing insert is a piercing disk insert inserted in a cylindrically-shaped container or vessel.

2. The device of claim 1, wherein the waste chamber and the buffer solution chamber are positioned in the top vessel such that the waste chamber and the buffer solutionAtty Ref. 341049: 61-24 WOare vertically aligned with at least one pierce tip configured to pierce the bottom film to fluidically access the buffer solution chamber at a first pierce location and to fluidically access the waste chamber at a second pierce location.

3. The device of any one of claims 1-2, wherein the sample chamber is removably connected to the membrane housing to provide a membrane housing removed configuration, wherein in the membrane housing removed configuration the membrane housing is configured to optically receive a magnifying cap to optically image the membrane pad to detect the presence or absence of one or more biomarkers.

4. The device of any one of claims 1-3, wherein the membrane housing contains a vertical flow immunoassay (VFI).

5. The device of any one of claims 1-4, wherein the passage is sized to receive a whole blood collection device that dispenses the biofluid that is a whole blood sample into the sample chamber.

6. The device of any one of claims 1-5, wherein the sample chamber is configured to receive a whole blood sample volume between 1 pL and 10 mL.

7. The device of any one of claims 1-6, wherein the sample chamber further comprises a capture agent immobilized on a wall that forms the sample container.

8. The device of claim 7, wherein the capture agent is selected from the group consisting of DNA probes, RNA probes, an antibody, a polypeptide, and any combination thereof.

9. The device of claim 7, wherein the capture agent is an antibody selected from the group consisting of S9.6 antibody, anti-CD3, anti-CD19, and anti-CD45.

10. The device of any one of claims 1-9, wherein the sample container is formed of a material comprising polycarbonate, polypropylene, styrene, or any combination of these.

11. A method of detecting a presence or an absence of a biomarker in a whole blood sample, the method comprising the steps ofproviding the device of any one of claims 1-10;loading a primary buffer solution comprising a red blood cell lysis buffer solution into the primary buffer solution chamber;loading a lateral buffer solution comprising a leukocyte cell lysis buffer solution into at least one lateral buffer solution chamber;loading the whole blood sample through the passage into the sample chamber;Atty Ref. 341049: 61-24 WOpiercing the top vessel bottom film to fluidically introduce the primary buffer solution to the whole blood sample;performing a first incubation step to process red blood cells and to immobilize leukocytes on a wall of the sample chamber;inverting the device;fluidically introducing any excess primary buffer solution to the waste chamber;sealing the waste chamber and piercing the one or more lateral buffer chambers to release the lateral buffer solution into the sample chamber; inverting the device a second time;performing a second incubation step to process the immobilized leukocytes; piercing the sample container film thereby fluidically introducing the leukocyte lysis buffer to the membrane pad;removing the sample chamber from the membrane housing; andoptically imaging the membrane pad for the presence of the biomarker, thereby detecting the presence or absence of the biomarker.

12. The method of claim 12, wherein the biomarker indicates an exposure to radiation.

13. The method of any one of claims 11-12, wherein the step of piercing the top vessel bottom film to fluidically introduce the primary buffer solution to the biofluid comprises applying a physical force to the top vessel in:a downward direction; and / ora rotational direction relative to the sample chamber.

14. The method of any one of clams 11-13, wherein the step of fluidically introducing any excess buffer solution to the waste chamber comprises: piercing the film at a waste chamber location by further continuing to rotate the top vessel relative to the sample container.

15. The method of any one of claims 11-14, wherein the step of sealing the waste chamber and piercing the lateral buffer chambers to release the later buffer solution comprises applying a second physical force to the top vessel in:a downward direction for a second time; and / ora continuing rotational direction relative to the sample chamber.

16. The method of any one of claims 11-15, further comprising the step of heating the device during a third incubation step.Atty Ref. 341049: 61-24 WO17. The method of any one of claims 11-16, wherein the first incubation step is for a first incubation time period selected from the range of 10 s to 10 min and the second incubation step is for a second incubation time period selected from the range of 10 s to 15 min.

18. The method of any one of claims 11-17, wherein the leukocyte cell lysis buffer solution further comprises a DNA probe solution and / or an RNA probe solution.

19. The method of any one of claims 11-18, used as a biodosimetry assay.

20. The method of any one of claims 11-19, wherein a plurality of biomarkers are detected, including a plurality of intracellular biomarkers, wherein the biomarker(s) are selected from the group consisting of: proteins, DNA sequence, RNA sequence, radiation responsive genes, and any combination thereof.

21. The method of any one of claims 11-20, wherein the biomarker comprises an intracellular protein selected from the group consisting of: ACTN1, DDB2, FDXR, phosphor-p53, TSPYL2, and any combination of thereof.

22. The method of any one of claims 11-21, wherein the biomarker is a radiation responsive gene that is an up-regulated gene or a downregulated gene, including the radiation responsive gene selected from the group consisting of CDKN1A, DDB2, TYMS, CD79B, MYC, EOMS, and any combination thereof.

23. The method of any one of claims 11-22, having a radiation detective sensitivity selected from a range of 0.1 Gy to 3 Gy, including 2 Gy.

24. The method of any one of claims 11-23, further comprising the step of collecting the whole blood sample from an individual, including from within 72 hours of a putative radiation exposure event.

25. The method of any one of claims 24, wherein the collecting is by a finger-stick.

26. The method of any one of claims 11-25, wherein the membrane pad layer corresponds to a VFI.